BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3897] [Article Influence: 256.5] [Reference Citation Analysis]
Number Citing Articles
1 Vitale A, D’Amico F, Frigo AC, Grigoletto F, Brolese A, Zanus G, Neri D, Carraro A, D’Amico FE, Burra P. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol. 2010;17:2290-2302. [PMID: 20217249 DOI: 10.1245/s10434-010-0993-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
2 Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25:240-247. [PMID: 24291001 DOI: 10.1016/j.jvir.2013.10.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
3 Zhu Y, Dong J, Wang WL, Li MX, Lu Y. Short- and long-term outcomes after salvage liver transplantation versus primary liver transplantation for hepatocellular carcinoma: a meta-analysis. Transplant Proc 2013;45:3329-42. [PMID: 24182812 DOI: 10.1016/j.transproceed.2013.06.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
4 Corona-Villalobos CP, Halappa VG, Bonekamp S, Eng J, Reyes D, Cosgrove D, Rastegar N, Pan L, Pawlik TM, Kamel IR. Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma. Invest Radiol. 2015;50:283-289. [PMID: 25396692 DOI: 10.1097/rli.0000000000000112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
5 Liang KH, Zhang P, Lin CL, Wang SC, Hu TH, Yeh CT, Su GL. Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients. Dig Dis Sci 2020;65:2130-9. [PMID: 31677071 DOI: 10.1007/s10620-019-05915-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25:74-85. [PMID: 27312032 DOI: 10.1016/j.suronc.2016.03.002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 175] [Article Influence: 33.0] [Reference Citation Analysis]
7 Chen BB, Shih TTF. DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol 2014; 20(12): 3125-3134 [PMID: 24695624 DOI: 10.3748/wjg.v20.i12.3125] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
8 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
9 Sohn W, Cho JY, Kim JH, Lee JI, Kim HJ, Woo MA, Jung SH, Paik YH. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. Clin Mol Hepatol 2017;23:170-8. [PMID: 28506056 DOI: 10.3350/cmh.2016.0086] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
10 Rodríguez-Sanjuán JC, González F, Juanco C, Herrera LA, López-Bautista M, González-Noriega M, García-Somacarrera E, Figols J, Gómez-Fleitas M, Silván M. Radiological and pathological assessment of hepatocellular carcinoma response to radiofrequency. A study on removed liver after transplantation. World J Surg. 2008;32:1489-1494. [PMID: 18373117 DOI: 10.1007/s00268-008-9559-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
11 Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver Ablation: Best Practice. Radiol Clin North Am 2015;53:933-71. [PMID: 26321447 DOI: 10.1016/j.rcl.2015.05.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
12 Chen Z, Xie B, Zhu Q, Xia Q, Jiang S, Cao R, Shi L, Qi D, Li X, Cai L. FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis. Int J Med Sci. 2013;10:1868-1875. [PMID: 24324363 DOI: 10.7150/ijms.6868] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
13 Ramirez P, Sáenz L, Cascales-campos P, González Sánchez M, Llàcer-millán E, Sánchez-lorencio M, Díaz-rubio E, De La Orden V, Mediero-valeros B, Navarro J, Revilla Nuin B, Baroja-mazo A, Noguera-velasco J, Sánchez B, de la Peña J, Pons-miñano J, Sánchez-bueno F, Robles-campos R, Parrilla P. Oncological Evaluation by Positron-emission Tomography, Circulating Tumor Cells and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma on the Waiting List for Liver Transplantation. Transplantation Proceedings 2016;48:2962-5. [DOI: 10.1016/j.transproceed.2016.07.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lim KC, Wang VW, Siddiqui FJ, Shi L, Chan ES, Oh HC, Tan SB, Chow PK. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology. 2015;61:227-237. [PMID: 24638991 DOI: 10.1002/hep.27135] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
15 Nguyen DL, Juran BD, Lazaridis KN. Primary biliary cirrhosis. Best Pract Res Clin Gastroenterol. 2010;24:647-654. [PMID: 20955967 DOI: 10.1016/j.bpg.2010.07.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
16 Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, Huo TI, Huang YH, Chau GY, Su CW, Yeh YC, Lin HC, Lee SD, Wu JC. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine (Baltimore) 2014;93:e348. [PMID: 25546689 DOI: 10.1097/MD.0000000000000348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Feng H, Fang F, Yuan L, Xiao M, Yang XY, Huang Y. Downregulated expression of CFHL1 is associated with unfavorable prognosis in postoperative patients with hepatocellular carcinoma. Exp Ther Med 2019;17:4073-9. [PMID: 31007744 DOI: 10.3892/etm.2019.7455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, Miller FH, Sato KT, Omary RA, Salem R. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009;49:1185-1193. [PMID: 19133645 DOI: 10.1002/hep.22747] [Cited by in Crossref: 185] [Cited by in F6Publishing: 162] [Article Influence: 15.4] [Reference Citation Analysis]
19 Chung J, Yu JS, Kim DJ, Chung JJ, Kim JH, Kim KW. Hypervascular hepatocellular carcinoma in the cirrhotic liver: diffusion-weighted imaging versus superparamagnetic iron oxide-enhanced MRI. Magn Reson Imaging 2011;29:1235-43. [PMID: 21907517 DOI: 10.1016/j.mri.2011.07.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Tateishi R, Shiina S, Akahane M, Sato J, Kondo Y, Masuzaki R, Nakagawa H, Asaoka Y, Goto T, Otomo K, Omata M, Yoshida H, Koike K. Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma. PLoS One 2013;8:e59040. [PMID: 23593129 DOI: 10.1371/journal.pone.0059040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
21 Xie X, Jiang C, Peng Z, Liu B, Hu W, Wang Y, Lin M, Lu M, Kuang M. Local Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma: Treatment Choice and Outcome. J Gastrointest Surg 2015;19:1466-75. [DOI: 10.1007/s11605-015-2850-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
22 Chen PH, Hsieh WY, Su CW, Hou MC, Wang YP, Hsin IF, Yang TC, Liao WC, Lin HC, Lee FY, Wu JC. Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinoma who does not require endoscopic screening for esophageal varices. Gastrointest Endosc. 2018;88:230-239.e2. [PMID: 29317268 DOI: 10.1016/j.gie.2017.12.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
23 Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY, Liu C, Qiu YH, Feng FL, Wang JH. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin. 2010;31:1643-1648. [PMID: 21102481 DOI: 10.1038/aps.2010.124] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
24 Sulkowski M. Hepatocellular carcinoma in HIV-infected patients comes of age: The convergence of epidemiology and treatment effectiveness. J Hepatol 2009;50:655-8. [PMID: 19243854 DOI: 10.1016/j.jhep.2009.01.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
25 Woo HY, Heo J. Sorafenib in liver cancer. Expert Opin Pharmacother. 2012;13:1059-1067. [PMID: 22519770 DOI: 10.1517/14656566.2012.679930] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
26 Koom WS, Park SY, Kim W, Kim M, Kim JS, Kim H, Choi IK, Yun CO, Seong J. Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma. J Radiat Res 2012;53:202-10. [PMID: 22510592 DOI: 10.1269/jrr.11110] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
27 Tsunematsu S, Suda G, Yamasaki K, Kimura M, Takaaki I, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Kamiyama T, Taketomi A, Sakamoto N. Combination of neutrophil-to-lymphocyte ratio and early des-γ-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. Hepatol Res 2017;47:533-41. [PMID: 27423140 DOI: 10.1111/hepr.12775] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
28 Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN;  HepNet. Greece Study Group. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. J Viral Hepat. 2015;22:120-127. [PMID: 25040685 DOI: 10.1111/jvh.12283] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
29 Yang YP, Qu JH, Chang XJ, Lu YY, Bai WL, Dong Z, Wang H, An LJ, Xu ZX, Wang CP. High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. J Transl Med. 2013;11:41. [PMID: 23414367 DOI: 10.1186/1479-5876-11-41] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
30 Wörns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S302-S309. [PMID: 20547319 DOI: 10.1016/S1590-8658(10)60521-X] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
31 Brito AF, Ribeiro M, Abrantes AM, Mamede AC, Laranjo M, Casalta-Lopes JE, Gonçalves AC, Sarmento-Ribeiro AB, Tralhão JG, Botelho MF. New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. Nutr Cancer 2016;68:250-66. [PMID: 26943884 DOI: 10.1080/01635581.2016.1145245] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
32 Qi X, Tang Y, An D, Bai M, Shi X, Wang J, Han G, Fan D. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2014;48:450-457. [PMID: 24172183 DOI: 10.1097/mcg.0000000000000008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 15] [Article Influence: 5.1] [Reference Citation Analysis]
33 Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol 2015; 7(8): 1020-1029 [PMID: 26052391 DOI: 10.4254/wjh.v7.i8.1020] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 13.5] [Reference Citation Analysis]
34 Chou C, Huang Y, Lee C, Lee K, Chen Y, Chen R. Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma in Interlobar Watershed Zone of Liver: Comparison of Unilateral and Bilateral Chemoembolization. Journal of Vascular and Interventional Radiology 2012;23:1036-42. [DOI: 10.1016/j.jvir.2012.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
35 Le Faouder J, Laouirem S, Chapelle M, Albuquerque M, Belghiti J, Degos F, Paradis V, Camadro J, Bedossa P. Imaging Mass Spectrometry Provides Fingerprints for Distinguishing Hepatocellular Carcinoma from Cirrhosis. J Proteome Res 2011;10:3755-65. [DOI: 10.1021/pr200372p] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
36 Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2008;2:779-88. [PMID: 19707458 DOI: 10.2147/btt.s3410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 0.3] [Reference Citation Analysis]
37 He N, Feng G, Zhang C, Wu F, Zhang T, Yang Y. Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis. Mol Med Rep 2020;22:2705-14. [PMID: 32945374 DOI: 10.3892/mmr.2020.11356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Heuman DM, Gilles HS, Solomon C, Bajaj JS. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? No. Eur J Intern Med. 2012;23:37-39. [PMID: 22153529 DOI: 10.1016/j.ejim.2011.09.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Trillaud H, Bruel JM, Valette PJ, Vilgrain V, Schmutz G, Oyen R, Jakubowski W, Danes J, Valek V, Greis C. Characterization of focal liver lesions with SonoVue®-enhanced sonography: International multicenter-study in comparison to CT and MRI. World J Gastroenterol 2009; 15(30): 3748-3756 [PMID: 19673015 DOI: 10.3748/wjg.15.3748] [Cited by in CrossRef: 123] [Cited by in F6Publishing: 94] [Article Influence: 10.3] [Reference Citation Analysis]
40 Parisi G. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? Yes. Eur J Intern Med. 2012;23:34-36. [PMID: 22153528 DOI: 10.1016/j.ejim.2011.10.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
41 Wu CK, Chang KC, Hung CH, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hu TH. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. J Antimicrob Chemother 2016;71:1943-7. [PMID: 27073265 DOI: 10.1093/jac/dkw097] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
42 Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89-99. [PMID: 18977551 DOI: 10.1016/j.jhep.2008.07.029] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 6.8] [Reference Citation Analysis]
43 Marrero JA, Ahn J, Rajender Reddy K; Americal College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol 2014;109:1328-47; quiz 1348. [PMID: 25135008 DOI: 10.1038/ajg.2014.213] [Cited by in Crossref: 184] [Cited by in F6Publishing: 133] [Article Influence: 26.3] [Reference Citation Analysis]
44 Wee A. Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. Cytopathology. 2011;22:287-305. [PMID: 21762411 DOI: 10.1111/j.1365-2303.2011.00882.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
45 Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol. 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Pan Y, Ni R, Deng Q, Huang X, Zhang Y, Lu C, Li F, Huang D, He S, Chen B. Glyoxylate Reductase/Hydroxypyruvate Reductase: A Novel Prognostic Marker for Hepatocellular Carcinoma Patients after Curative Resection. Pathobiology 2013;80:155-62. [DOI: 10.1159/000346476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Outwater EK. Imaging of the liver for hepatocellular cancer. Cancer Control. 2010;17:72-82. [PMID: 20404790 DOI: 10.1177/107327481001700202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
48 Su F, Ioannou GN. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. Curr Hepatol Rep 2018;17:377-84. [PMID: 30923667 DOI: 10.1007/s11901-018-0424-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
49 Pacella CM, Francica G, Di Costanzo GG. Laser ablation for small hepatocellular carcinoma. Radiol Res Pract. 2011;2011:595627. [PMID: 22191028 DOI: 10.1155/2011/595627] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
50 Pol S, Marcellin P. Prise en charge de l’hépatite C en 2008. Gastroentérologie Clinique et Biologique 2008;32:S121-4. [DOI: 10.1016/s0399-8320(08)73275-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update. World J Gastroenterol 2013; 19(42): 7316-7326 [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
52 Pinato DJ, Karamanakos G, Ishizuka M, Smirne C, Pirisi M, Kubota K, Sharma R. The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application. Liver Int 2015;35:2458-65. [PMID: 25845291 DOI: 10.1111/liv.12841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
53 Choi HJ, Kim DG, Na GH, Hong TH, You YK. Extended criteria for living donor liver transplantation in patients with advanced hepatocellular carcinoma. Transplant Proc. 2012;44:399-402. [PMID: 22410027 DOI: 10.1016/j.transproceed.2012.01.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
54 Sinakos E, Dedes I, Papalavrentios L, Drevelegas A, Akriviadis E. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. Scandinavian Journal of Gastroenterology 2010;45:511-2. [DOI: 10.3109/00365521003628335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
55 Park G, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 2010;83:1010-6. [PMID: 20682591 DOI: 10.1259/bjr/66686028] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
56 Alencar R, Gomes M, Sitnik R, Pinho J, Malta F, Mello I, Mello E, Bacchella T, Machado M, Alves V, Carrilho F. Low occurrence of occult hepatitis B virus infection and high frequency of hepatitis C virus genotype 3 in hepatocellular carcinoma in Brazil. Braz J Med Biol Res 2008;41:235-40. [DOI: 10.1590/s0100-879x2006005000197] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
57 Abu El Makarem MA, Abdel-aleem A, Ali A, Saber R, Shatat M, Rahem DA, Sayed D. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Annals of Hepatology 2011;10:296-305. [DOI: 10.1016/s1665-2681(19)31541-8] [Cited by in Crossref: 40] [Article Influence: 4.0] [Reference Citation Analysis]
58 Bruguera M. Historia de la hepatología en Cataluña. Gastroenterología y Hepatología 2013;36:484-91. [DOI: 10.1016/j.gastrohep.2013.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Cai M, Shao W, Yu H, Hong Y, Shi L. Paeonol Inhibits Cell Proliferation, Migration and Invasion and Induces Apoptosis in Hepatocellular Carcinoma by Regulating miR-21-5p/KLF6 Axis. Cancer Manag Res 2020;12:5931-43. [PMID: 32765094 DOI: 10.2147/CMAR.S254485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
60 Gao L, Lv G, Li R, Liu WT, Zong C, Ye F, Li XY, Yang X, Jiang JH, Hou XJ, Jing YY, Han ZP, Wei LX. Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation. Cancer Lett 2019;454:215-23. [PMID: 30980867 DOI: 10.1016/j.canlet.2019.04.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
61 Qi X, Guo X. Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies. Prz Gastroenterol. 2015;10:142-147. [PMID: 26516379 DOI: 10.5114/pg.2015.52470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
62 Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011;43:205-11. [PMID: 22247704 DOI: 10.4143/crt.2011.43.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
63 Hassan HM, El-Kannishy SMH, Alattar A, Alshaman R, Hamdan AM, Al-Gayyar MMH. Therapeutic effects of blocking β-catenin against hepatocellular carcinoma-induced activation of inflammation, fibrosis and tumor invasion. Biomed Pharmacother 2021;135:111216. [PMID: 33433352 DOI: 10.1016/j.biopha.2021.111216] [Reference Citation Analysis]
64 Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis. 2010;42:341-347. [PMID: 19828388 DOI: 10.1016/j.dld.2009.09.002] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 8.3] [Reference Citation Analysis]
65 Rode A. [Radiological treatment of hepatocellular carcinoma in 2010]. Cancer Radiother 2011;15:21-7. [PMID: 21257330 DOI: 10.1016/j.canrad.2010.11.002] [Reference Citation Analysis]
66 Sherman M, Groszmann RJ, Iwakiri Y, Taddei TH. Whither hepatocellular carcinoma screening? Hepatology 2012;56:2412-4. [DOI: 10.1002/hep.26138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
67 Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291-297. [PMID: 20483497 DOI: 10.1016/j.jhep.2010.03.010] [Cited by in Crossref: 184] [Cited by in F6Publishing: 171] [Article Influence: 16.7] [Reference Citation Analysis]
68 Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A. Placement of a Sodium Hyaluronate Solution onto the Liver Surface as a Supportive Procedure for Radiofrequency Ablation of Hepatocellular Carcinomas Located on the Liver Surface: A Preliminary Report. Journal of Vascular and Interventional Radiology 2012;23:1639-1645.e1. [DOI: 10.1016/j.jvir.2012.08.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
69 Teixeira AC, Mendes CT, Marano LA, Deghaide NH, Secaf M, Elias J, Muglia V, Donadi EA, Martinelli AL. Alleles and genotypes of polymorphisms of IL-18, TNF-α and IFN-γ are associated with a higher risk and severity of hepatocellular carcinoma (HCC) in Brazil. Hum Immunol. 2013;74:1024-1029. [PMID: 23632060 DOI: 10.1016/j.humimm.2013.04.029] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
70 Qin W, Wang L, Hu B, Leng S, Tian H, Luo H, Yao J, Chen X, Wu C, Chen G, Yang Y. A Novel Score Predicts HBV-Related Hepatocellular Carcinoma Recurrence After Hepatectomy: a Retrospective Multicenter Study. J Gastrointest Surg 2019;23:922-32. [PMID: 30446938 DOI: 10.1007/s11605-018-4037-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
71 Lee YB, Nam JY, Lee JH, Chang Y, Cho H, Cho YY, Cho EJ, Yu SJ, Kim HY, Lee DH, Lee JM, Hwang SG, Kim YJ, Yoon JH. Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. Sci Rep 2018;8:13651. [PMID: 30209336 DOI: 10.1038/s41598-018-31839-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Li Z, Lei Z, Xia Y, Li J, Wang K, Zhang H, Wan X, Yang T, Zhou W, Wu M, Pawlik TM, Lau WY, Shen F. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surg 2018;153:e182721. [PMID: 30073257 DOI: 10.1001/jamasurg.2018.2721] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
73 Amarapurkar D. Screening for hepatocellular carcinoma: Good enough but best yet to come: Editorials. Journal of Gastroenterology and Hepatology 2010;25:845-6. [DOI: 10.1111/j.1440-1746.2010.06276.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:425-33. [PMID: 19072390 DOI: 10.1586/17474124.2.3.425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
75 Yang L, Ling Y, Zhang Z, Zhao Q, Tang J, Ji H, Zhang Y. ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways. Biochemical and Biophysical Research Communications 2011;409:752-7. [DOI: 10.1016/j.bbrc.2011.05.083] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
76 Wu J, Zhang Z, Zhu P, Mba'nbo-koumpa A, Zhang B, Chen X, Shu C, Zhang W, Feng R, Li G. Comparative liver function models for ruptured hepatocellular carcinoma: A 10-year single center experience. Asian Journal of Surgery 2019;42:874-82. [DOI: 10.1016/j.asjsur.2018.12.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
77 Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914-921. [PMID: 18177453 DOI: 10.1111/j.1572-0241.2007.01712.x] [Cited by in Crossref: 258] [Cited by in F6Publishing: 268] [Article Influence: 19.8] [Reference Citation Analysis]
78 Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18:413-420. [PMID: 20839057 DOI: 10.1245/s10434-010-1321-8] [Cited by in Crossref: 205] [Cited by in F6Publishing: 219] [Article Influence: 18.6] [Reference Citation Analysis]
79 Le PH, Liang KH, Chang ML, Hsu CW, Chen YC, Lin CL, Lin WR, Lai MW, Yeh CT. Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment. In Vivo. 2017;31:723-729. [PMID: 28652447 DOI: 10.21873/invivo.11121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
80 Melloul E, Lesurtel M, Carr BI, Clavien PA. Developments in liver transplantation for hepatocellular carcinoma. Semin Oncol. 2012;39:510-521. [PMID: 22846868 DOI: 10.1053/j.seminoncol.2012.05.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
81 Kitada T, Murakami T, Kuzushita N, Minamitani K, Nakajo K, Osuga K, Miyoshi E, Nakamura H, Kishino B, Tamura S, Hayashi N. Effectiveness of real-time virtual sonography-guided radiofrequency ablation treatment for patients with hepatocellular carcinomas. Hepatol Res 2008;38:565-71. [PMID: 18218008 DOI: 10.1111/j.1872-034X.2007.00308.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
82 Chu CM, Lin CC, Chen YC, Jeng WJ, Lin SM, Liaw YF. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer 2012;107:2010-5. [PMID: 23079574 DOI: 10.1038/bjc.2012.474] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
83 Akagi M, Nakamura Y, Higaki T, Matsubara Y, Terada H, Honda Y, Tatsugami F, Baba Y, Iida M, Awai K. Preliminary Results of High-Precision Computed Diffusion Weighted Imaging for the Diagnosis of Hepatocellular Carcinoma at 3 Tesla. J Comput Assist Tomogr 2018;42:373-9. [PMID: 29287019 DOI: 10.1097/RCT.0000000000000702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
84 Jia H, Yang Q, Wang T, Cao Y, Jiang QY, Ma HD, Sun HW, Hou MX, Yang YP, Feng F. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents. Biochim Biophys Acta 2016;1860:1417-30. [PMID: 27091611 DOI: 10.1016/j.bbagen.2016.04.007] [Cited by in Crossref: 51] [Cited by in F6Publishing: 68] [Article Influence: 10.2] [Reference Citation Analysis]
85 Gao J, Zhen R, Liao H, Zhuang W, Guo W. Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. Oncol Lett. 2018;15:7175-7181. [PMID: 29725440 DOI: 10.3892/ol.2018.8242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
86 Eriguchi T, Takeda A, Tateishi Y, Tsurugai Y, Sanuki N, Ebinuma H, Horita N. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies. Hepatol Res 2021;51:813-22. [PMID: 33856722 DOI: 10.1111/hepr.13647] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 You Z, Chen LP, Ye H. Predictors of microvascular invasion in patients with solitary small hepatitis B related hepatocellular carcinoma. Pak J Med Sci 2014;30:331-4. [PMID: 24772137 DOI: 10.12669/pjms.302.4652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
88 White JA, Redden DT, Bryant MK, Dorn D, Saddekni S, Abdel Aal AK, Zarzour J, Bolus D, Smith JK, Gray S, Eckhoff DE, DuBay DA. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) 2014;16:1095-101. [PMID: 25158123 DOI: 10.1111/hpb.12313] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
89 Liu FY, Wang MQ, Duan F, Fan QS, Song P, Wang Y. Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization. BMC Gastroenterol 2013;13:105. [PMID: 23800233 DOI: 10.1186/1471-230X-13-105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
90 Guo LH, Xu HX. Contrast-Enhanced Ultrasound in the Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Controversy over the ASSLD Guideline. Biomed Res Int 2015;2015:349172. [PMID: 26090401 DOI: 10.1155/2015/349172] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
91 Cereser L, Furlan A, Bagatto D, Girometti R, Como G, Avellini C, Orsaria M, Zuiani C, Bazzocchi M. Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma. J Comput Assist Tomogr 2010;34:706-11. [PMID: 20861773 DOI: 10.1097/RCT.0b013e3181e1a88e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
92 Ren Y, Yang L, Li M, Wang J, Yan H, Ma N, Liu W, Wang L, Gao X, Gao P, Li T, Liu D. 4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients. Sci Rep 2021;11:16982. [PMID: 34417517 DOI: 10.1038/s41598-021-96581-4] [Reference Citation Analysis]
93 Sánchez Antolín G, García Pajares F, Pérez E, Villacastín E, Ruiz Rebollo L, Sánchez DP, Cítores MA, Velicia Llames R. Milan criteria versus San Francisco criteria in hepatocellular carcinoma: our center's experience. Transplant Proc 2009;41:1012-3. [PMID: 19376413 DOI: 10.1016/j.transproceed.2009.02.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
94 Sohn BH, Park IY, Shin JH, Yim SY, Lee JS. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells. Exp Mol Med 2018;50:e421. [PMID: 29303508 DOI: 10.1038/emm.2017.174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
95 Nakayama H, Takayama T, Okubo T, Higaki T, Midorikawa Y, Moriguchi M, Itoh A. Proposal of objective morphological classification system for hepatocellular carcinoma using preoperative multiphase computed tomography. J Gastroenterol. 2014;49:1430-1437. [PMID: 24240709 DOI: 10.1007/s00535-013-0908-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
96 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
97 Yoo BK, Emdad L, Gredler R, Fuller C, Dumur CI, Jones KH, Jackson-Cook C, Su ZZ, Chen D, Saxena UH, Hansen U, Fisher PB, Sarkar D. Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma. Proc Natl Acad Sci U S A 2010;107:8357-62. [PMID: 20404171 DOI: 10.1073/pnas.1000374107] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
98 Mohan N, González-Peralta RP, Fujisawa T, Chang MH, Heller S, Jara P, Kelly D, Mieli-Vergani G, Shah U, Murray KF. Chronic hepatitis C virus infection in children. J Pediatr Gastroenterol Nutr. 2010;50:123-131. [PMID: 20038846 DOI: 10.1097/mpg.0b013e3181c61995] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
99 Mao X, Guo Y, Wen F, Liang H, Sun W, Lu Z. Applying arterial enhancement fraction (AEF) texture features to predict the tumor response in hepatocellular carcinoma (HCC) treated with Transarterial chemoembolization (TACE). Cancer Imaging 2021;21:49. [PMID: 34384496 DOI: 10.1186/s40644-021-00418-2] [Reference Citation Analysis]
100 Yang Y, Lin K, Liu L, Qian Y, Yang Y, Yuan S, Zhu P, Huang J, Liu F, Gu F, Fu S, Jiang B, Liu H, Pan Z, Lau WY, Zhou W. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis. Cancer Med 2021;10:2100-11. [PMID: 33650288 DOI: 10.1002/cam4.3814] [Reference Citation Analysis]
101 Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S. Hepatic resection for “BCLC stage A” hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol. 2012;19:426-434. [PMID: 21732145 DOI: 10.1245/s10434-011-1845-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
102 Boozari B, Soudah B, Rifai K, Schneidewind S, Vogel A, Hecker H, Hahn A, Schlue J, Dietrich CF, Bahr MJ. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography - a prospective study. Dig Liver Dis. 2011;43:484-490. [PMID: 21377941 DOI: 10.1016/j.dld.2011.01.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
103 Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, Bomford A, O'Grady JG, Harrison PM, Heneghan MA. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology. 2008;48:863-870. [PMID: 18752332 DOI: 10.1002/hep.22432] [Cited by in Crossref: 123] [Cited by in F6Publishing: 96] [Article Influence: 9.5] [Reference Citation Analysis]
104 Tsai MY, Yen YH, Huang PY, Sou FM, Lin CC, Cho WR, Wang HM, Chen DW, Chang KC, Wu CK, Hu TH, Tsai MC. The Pre- and Postoperative FIB-4 Indexes Are Good Predictors to the Outcomes of HBV-Related HCC Patients after Resection. Gastroenterol Res Pract 2019;2019:8945798. [PMID: 31885547 DOI: 10.1155/2019/8945798] [Reference Citation Analysis]
105 Toyama T, Nitta N, Ohta S, Tanaka T, Nagatani Y, Takahashi M, Murata K, Shiomi H, Naka S, Kurumi Y, Tani T, Tabata Y. Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. Jpn J Radiol 2012;30:62-8. [PMID: 22194039 DOI: 10.1007/s11604-011-0010-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
106 Reig M, Torres F, Rodriguez-lope C, Forner A, Llarch N, Rimola J, Darnell A, Ríos J, Ayuso C, Bruix J. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. Journal of Hepatology 2014;61:318-24. [DOI: 10.1016/j.jhep.2014.03.030] [Cited by in Crossref: 146] [Cited by in F6Publishing: 142] [Article Influence: 20.9] [Reference Citation Analysis]
107 Trinchet J. Carcinome hépatocellulaire : une incidence croissante, une prise en charge « optimisée ». Gastroentérologie Clinique et Biologique 2009;33:830-9. [DOI: 10.1016/j.gcb.2009.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
108 Shaker MK, Abdella HM, Khalifa MO, El Dorry AK. Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int. 2013;33:1601-1606. [PMID: 23714212 DOI: 10.1111/liv.12209] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
109 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
110 Cheng J, Xie HY, Xu X, Wu J, Wei X, Su R, Zhang W, Lv Z, Zheng S, Zhou L. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011;310:35-45. [PMID: 21763068 DOI: 10.1016/j.canlet.2011.06.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
111 Toyoda H, Tada T, Yasuda S, Mizuno K, Ito T, Kumada T. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response. Clin Infect Dis 2020;70:1208-14. [PMID: 31056696 DOI: 10.1093/cid/ciz359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
112 Castroagudín JF, Molina-Pérez E, Ferreiro-Iglesias R, Abdulkader I, Otero-Antón E, Tomé S, Varo-Pérez E. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed? Transplant Proc. 2012;44:1565-1567. [PMID: 22841215 DOI: 10.1016/j.transproceed.2012.05.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
113 Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019;39:2008-2023. [PMID: 31433891 DOI: 10.1111/liv.14220] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
114 Kang TW, Kim JM, Rhim H, Lee MW, Kim YS, Lim HK, Choi D, Song KD, Kwon CH, Joh JW, Paik SW, Paik YH, Ahn JH. Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection--Propensity Score Analyses of Long-term Outcomes. Radiology. 2015;275:908-919. [PMID: 25688888 DOI: 10.1148/radiol.15141483] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
115 Lin MT, Wang CC, Cheng YF, Eng HL, Yen YH, Tsai MC, Tseng PL, Chang KC, Wu CK, Hu TH. Comprehensive Comparison of Multiple-Detector Computed Tomography and Dynamic Magnetic Resonance Imaging in the Diagnosis of Hepatocellular Carcinoma with Varying Degrees of Fibrosis. PLoS One 2016;11:e0166157. [PMID: 27829060 DOI: 10.1371/journal.pone.0166157] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
116 Miller G, Schwartz LH, D'Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am. 2007;16:343-368. [PMID: 17560517 DOI: 10.1016/j.soc.2007.04.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
117 Gramenzi A, Conti F, Felline F, Cursaro C, Riili A, Salerno M, Gitto S, Micco L, Scuteri A, Andreone P. Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study. J Viral Hepat. 2010;17:360-366. [PMID: 19758274 DOI: 10.1111/j.1365-2893.2009.01189.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
118 Leung HWC, Chan ALF. Cost-utility of stereotactic radiation therapy versus proton beam therapy for inoperable advanced hepatocellular carcinoma. Oncotarget. 2017;8:75568-75576. [PMID: 29088891 DOI: 10.18632/oncotarget.17369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
119 Jing YY, Liu WT, Guo SW, Ye F, Fan QM, Yu GF, Yu DD, Gao L, Sun K, Han ZP, Li R, Yang Y, Zhao QD, Wu MC, Wang HY, Wei LX. Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk. Oncotarget 2015;6:42952-62. [PMID: 26515593 DOI: 10.18632/oncotarget.5518] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
120 Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22:391-398. [PMID: 19940784 DOI: 10.1097/meg.0b013e328333df23] [Cited by in Crossref: 44] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
121 Giannini EG, Marenco S, Boni S, Beltrame A, Nicolini LA, Taramasso L, Feasi M, Grasso A, De Leo P, Percario G, Bartolacci V, Artioli S, Viscoli C, Cassola G, Testa R, Anselmo M, Riccio G, Savarino V, Picciotto A. Therapeutic Management of Chronic Hepatitis B in Clinical Practice: A Region-wide Survey. Journal of Clinical Gastroenterology 2015;49:228-34. [DOI: 10.1097/mcg.0000000000000106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
122 Di Costanzo GG, Tortora R, Morisco F, Addario L, Guarino M, Cordone G, Falco L, Caporaso N. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. Target Oncol. 2017;12:61-67. [PMID: 27503006 DOI: 10.1007/s11523-016-0454-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
123 Aryal B, Shimizu T, Kadono J, Furoi A, Komokata T, Kitazono I, Koriyama C, Yamakuchi M, Hashiguchi T, Imoto Y. Post-Resection Exhaustion of Intra-Platelet Serotonin: Also an Indicator of Early Hepatocellular Carcinoma Recurrence? J Cancer 2017;8:3984-91. [PMID: 29187873 DOI: 10.7150/jca.20971] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
124 Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, Luo J, Xu L, Zou RH, Lin XJ, Zhang YQ. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst. 2013;105:59-68. [PMID: 23150720 DOI: 10.1093/jnci/djs464] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
125 Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;10:78. [PMID: 20618937 DOI: 10.1186/1471-230x-10-78] [Cited by in Crossref: 116] [Cited by in F6Publishing: 60] [Article Influence: 10.5] [Reference Citation Analysis]
126 Yuan XD, Wang JW, Fang Y, Qian Y, Gao S, Fan YC, Wang K. Methylation status of the T-cadherin gene promotor in peripheral blood mononuclear cells is associated with HBV-related hepatocellular carcinoma progression. Pathol Res Pract 2020;216:152914. [PMID: 32147273 DOI: 10.1016/j.prp.2020.152914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Pouponneau P, Leroux J, Martel S. Magnetic nanoparticles encapsulated into biodegradable microparticles steered with an upgraded magnetic resonance imaging system for tumor chemoembolization. Biomaterials 2009;30:6327-32. [DOI: 10.1016/j.biomaterials.2009.08.005] [Cited by in Crossref: 106] [Cited by in F6Publishing: 66] [Article Influence: 8.8] [Reference Citation Analysis]
128 Rhim H, Choi D, Kim YS, Lim HK, Choe BK. Ultrasonography-guided percutaneous radiofrequency ablation of hepatocellular carcinomas: a feasibility scoring system for planning sonography. Eur J Radiol. 2010;75:253-258. [PMID: 19427152 DOI: 10.1016/j.ejrad.2009.04.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
129 Li Y, Ruan D, Yi H, Wang G, Yang Y, Jiang N. A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function. Hepatobiliary & Pancreatic Diseases International 2015;14:477-84. [DOI: 10.1016/s1499-3872(15)60412-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
130 Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, Shibuya A, Kobayashi S, Ohkawa S, Okuse C, Morita S, Taguri M, Tanaka K. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011;41:296-302. [PMID: 21348907 DOI: 10.1111/j.1872-034x.2011.00778.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
131 Khalili M, Guy J, Yu A, Li A, Diamond-Smith N, Stewart S, Chen M Jr, Nguyen T. Hepatitis B and hepatocellular carcinoma screening among Asian Americans: survey of safety net healthcare providers. Dig Dis Sci. 2011;56:1516-1523. [PMID: 21046247 DOI: 10.1007/s10620-010-1439-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
132 Feng K, Ma KS. Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 5987-5998 [PMID: 24876721 DOI: 10.3748/wjg.v20.i20.5987] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
133 Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-31. [PMID: 21703203 DOI: 10.1016/j.jhep.2011.02.034] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 9.3] [Reference Citation Analysis]
134 Bruno S, Savojardo D, Almasio PL, Mondelli MU. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med 2011;3:21-8. [PMID: 24367218 DOI: 10.2147/HMER.S16991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
135 Tan J, Zhao C, Peng N, Yang Y, Zhong J, Yang T, Zheng M, Wang Y, Gong W, Xiang B, Li L. Association between age and overall survival of patients with hepatocellular carcinoma after hepatic resection: Association of Age and Outcome Among HCC. J Surg Oncol 2016;114:966-70. [DOI: 10.1002/jso.24434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
136 Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011;80:373-381. [PMID: 21822028 DOI: 10.1159/000329040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
137 Ye SL, Yang J, Bie P, Zhang S, Chen X, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Lv Z. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. BMC Cancer 2018;18:247. [PMID: 29499662 DOI: 10.1186/s12885-018-4144-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
138 Dipasquale A, Marinello A, Santoro A. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. J Hepatocell Carcinoma 2021;8:241-51. [PMID: 33884259 DOI: 10.2147/JHC.S270532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R. A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization. American Journal of Transplantation 2009;9:1920-8. [DOI: 10.1111/j.1600-6143.2009.02695.x] [Cited by in Crossref: 361] [Cited by in F6Publishing: 316] [Article Influence: 30.1] [Reference Citation Analysis]
140 Blanc JF, Debaillon-Vesque A, Roth G, Barbare JC, Baumann AS, Boige V, Boudjema K, Bouattour M, Crehange G, Dauvois B, Decaens T, Dewaele F, Farges O, Guiu B, Hollebecque A, Merle P, Selves J, Aparicio T, Ruiz I, Bouché O; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association Française pour l’Etude du Foie (AFEF). Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clin Res Hepatol Gastroenterol 2021;45:101590. [PMID: 33780876 DOI: 10.1016/j.clinre.2020.101590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Béguelin C, Fall F, Seydi M, Wandeler G. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. Expert Rev Gastroenterol Hepatol 2018;12:537-46. [PMID: 29737218 DOI: 10.1080/17474124.2018.1474097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
142 Khorsandi SE, Heaton N. Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence. Transl Gastroenterol Hepatol 2016;1:25. [PMID: 28138592 DOI: 10.21037/tgh.2016.03.18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
143 Francica G, Petrolati A, Di Stasio E, Pacella S, Stasi R, Pacella CM. Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location. AJR Am J Roentgenol. 2012;199:1393-1401. [PMID: 23169736 DOI: 10.2214/ajr.11.7850] [Cited by in Crossref: 34] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
144 Llovet JM. Hepatocellular Carcinoma: Patients With Increasing Alpha-Fetoprotein But No Mass on Ultrasound. Clinical Gastroenterology and Hepatology 2006;4:29-35. [DOI: 10.1016/s1542-3565(05)00864-5] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
145 Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 2018;7:17. [PMID: 30087805 DOI: 10.1186/s40164-018-0109-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 14.7] [Reference Citation Analysis]
146 Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
147 Kogiso T, Nagahara H, Hashimoto E, Ariizumi S, Yamamoto M, Shiratori K. Efficient induction of apoptosis by wee1 kinase inhibition in hepatocellular carcinoma cells. PLoS One. 2014;9:e100495. [PMID: 24960176 DOI: 10.1371/journal.pone.0100495] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
148 Sun Q, Li J, Jin B, Wang T, Gu J. Evaluation of miR-331-3p and miR-23b-3p as serum biomarkers for hepatitis c virus-related hepatocellular carcinoma at early stage. Clin Res Hepatol Gastroenterol 2020;44:21-8. [PMID: 31053500 DOI: 10.1016/j.clinre.2019.03.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
149 Tayob N, Richardson P, White DL, Yu X, Davila JA, Kanwal F, Feng Z, El-Serag HB. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 2018;18:1. [PMID: 29301497 DOI: 10.1186/s12874-017-0458-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
150 Phillips AA, Justman JE. Screening HIV-infected patients for non-AIDS-defining malignancies. Curr HIV/AIDS Rep 2009;6:83-92. [PMID: 19358779 DOI: 10.1007/s11904-009-0013-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
151 Yao S, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: A state-of-the-art review. World J Gastrointest Oncol 2021; 13(11): 1599-1615 [DOI: 10.4251/wjgo.v13.i11.1599] [Reference Citation Analysis]
152 Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol 2013; 19(27): 4400-4408 [PMID: 23885153 DOI: 10.3748/wjg.v19.i27.4400] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
153 Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, Makowiec F, Obermaier R, Hopt UT, Blum HE. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology. 2008;48:1821-1833. [PMID: 19003875 DOI: 10.1002/hep.22535] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
154 Lee B, Liu K, Wu C, Huang K, Ho C, Hu R, Ho M, Wu Y, Lee P, Liang P. Comparison of Radiofrequency Ablation and Transarterial Chemoembolization for Hepatocellular Carcinoma in the Caudate Lobe. Cardiovasc Intervent Radiol 2018;41:1699-707. [DOI: 10.1007/s00270-018-1978-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
155 Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013;12:530-547. [PMID: 23400006 DOI: 10.1102/1470-7330.2012.0044] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 10.8] [Reference Citation Analysis]
156 Lei J, Wang W, Yan L. Downstaging Advanced Hepatocellular Carcinoma to the Milan Criteria May Provide a Comparable Outcome to Conventional Milan Criteria. J Gastrointest Surg 2013;17:1440-6. [DOI: 10.1007/s11605-013-2229-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
157 Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int. 2014;27:32-41. [PMID: 24118272 DOI: 10.1111/tri.12191] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 10.3] [Reference Citation Analysis]
158 Caturelli E, de Sio I. Biopsy diagnosis of hepatocellular carcinoma. Hepatology 2008;47:2145-2145. [DOI: 10.1002/hep.22282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
159 Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: Present and future: Novel treatment for liver cancer. Journal of Gastroenterology and Hepatology 2012;27:862-72. [DOI: 10.1111/j.1440-1746.2012.07096.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
160 Chen T, Chang T, Huang P, Tsai M, Lin L, Liu C, Ho K, Siauw C, Chao P, Tung J. Management and patient survival in hepatocellular carcinoma: Does the physician's level of experience matter? Journal of Gastroenterology and Hepatology 2008;23:e179-88. [DOI: 10.1111/j.1440-1746.2008.05341.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
161 Yong C, Tsai M, Lin C, Wang C, Lu S, Hung C, Hu T, Chen C. Comparison of Salvage Living Donor Liver Transplantation and Local Regional Therapy for Recurrent Hepatocellular Carcinoma. World J Surg 2016;40:2472-80. [DOI: 10.1007/s00268-016-3559-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
162 Wu CS, Yen CJ, Chou RH, Li ST, Huang WC, Ren CT, Wu CY, Yu YL. Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma. PLoS One 2012;7:e39466. [PMID: 22808038 DOI: 10.1371/journal.pone.0039466] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
163 Kim JH, Yeon JE, Jong YK, Seo WK, Cha IH, Seo TS, Park JJ, Kim JS, Bak YT, Byun KS. Spinal cord injury subsequent to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Dig Liver Dis. 2010;42:67-70. [PMID: 19546038 DOI: 10.1016/j.dld.2009.05.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
164 Lencioni R. Evolving strategies in the diagnosis of hepatocellular carcinoma. J Hepatol. 2011;54:184-186. [PMID: 20950887 DOI: 10.1016/j.jhep.2010.07.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
165 Lin M, Liao W, Dong M, Zhu R, Xiao J, Sun T, Chen Z, Wu B, Jin J. Exosomal neutral sphingomyelinase 1 suppresses hepatocellular carcinoma via decreasing the ratio of sphingomyelin/ceramide. FEBS J 2018;285:3835-48. [PMID: 30106227 DOI: 10.1111/febs.14635] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
166 Irtan S, Barbier L, Francoz C, Dondéro F, Durand F, Belghiti J. Liver transplantation for hepatocellular carcinoma: is zero recurrence theoretically possible? Hepatobiliary & Pancreatic Diseases International 2016;15:147-51. [DOI: 10.1016/s1499-3872(16)60069-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
167 Yoo EJ, Shin HS, Kim SU, Joo DJ, Park JY, Choi GH, Kim DY, Ahn SH, Seong J, Koh MJ, Han KH, Chon CY. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2013;6:755-9. [PMID: 23836988 DOI: 10.2147/OTT.S45602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
168 Huang J, Hernandez-Alejandro R, Croome KP, Zeng Y, Wu H, Chen Z. Hepatic resection for huge (>15 cm) multinodular HCC with macrovascular invasion. J Surg Res. 2012;178:743-750. [PMID: 22656039 DOI: 10.1016/j.jss.2012.04.058] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
169 Buijs M, Vossen JA, Geschwind JF, Salibi N, Pan L, Ventura VP, Liapi E, Lee KH, Kamel IR. Quantitative proton MR spectroscopy as a biomarker of tumor necrosis in the rabbit VX2 liver tumor. J Vasc Interv Radiol. 2011;22:1175-1180. [PMID: 21620723 DOI: 10.1016/j.jvir.2011.03.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
170 Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative Neutrophil to Lymphocyte Ratio and Prognostic Nutritional Index Predict Overall Survival After Hepatectomy for Hepatocellular Carcinoma. World J Surg 2015;39:1501-9. [DOI: 10.1007/s00268-015-2982-z] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 12.3] [Reference Citation Analysis]
171 Takechi M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M, Mochizuki T. Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. Jpn J Radiol. 2012;30:743-751. [PMID: 23001373 DOI: 10.1007/s11604-012-0120-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
172 Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21:327-332. [PMID: 20097098 DOI: 10.1016/j.jvir.2009.10.038] [Cited by in Crossref: 96] [Cited by in F6Publishing: 85] [Article Influence: 8.7] [Reference Citation Analysis]
173 Cerreto M, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. Nutrients 2021;13:2649. [PMID: 34444807 DOI: 10.3390/nu13082649] [Reference Citation Analysis]
174 Lee JJ, Kim PTW, Fischer S, Fung S, Gallinger S, Mcgilvray I, Moulton C, Wei AC, Greig PD, Cleary SP. Impact of Viral Hepatitis on Outcomes after Liver Resection for Hepatocellular Carcinoma: Results from a North American Center. Ann Surg Oncol 2014;21:2708-16. [DOI: 10.1245/s10434-014-3609-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
175 Iñarrairaegui M, Sangro B. Diagnóstico del hepatocarcinoma de pequeño tamaño. Gastroenterología y Hepatología 2007;30:498-505. [DOI: 10.1157/13110493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
176 Gervais DA, Arellano RS. Percutaneous tumor ablation for hepatocellular carcinoma. AJR Am J Roentgenol. 2011;197:789-794. [PMID: 21940565 DOI: 10.2214/ajr.11.7656] [Cited by in Crossref: 46] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
177 Seo YS, Kim JN, Keum B, Park S, Kwon YD, Kim YS, Jeen YT, Chun HJ, Kim CY, Kim CD, Ryu HS, Um SH. Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma. World J Gastroenterol 2008; 14(15): 2394-2400 [PMID: 18416468 DOI: 10.3748/wjg.14.2394] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
178 Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, Kim EH, Seong J, Lee DY, Han K. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. Liver Int 2012;32:1120-7. [DOI: 10.1111/j.1478-3231.2012.02811.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 7.4] [Reference Citation Analysis]
179 Guerrisi A, Marin D, Nelson RC, De Filippis G, Di Martino M, Barnhart H, Masciangelo R, Guerrisi I, Passariello R, Catalano C. Effect of varying contrast material iodine concentration and injection technique on the conspicuity of hepatocellular carcinoma during 64-section MDCT of patients with cirrhosis. Br J Radiol 2011;84:698-708. [PMID: 21750137 DOI: 10.1259/bjr/21539234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
180 Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007;5:508-12. [PMID: 17382601 DOI: 10.1016/j.cgh.2007.01.014] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
181 Sersté T, Barrau V, Ozenne V, Vullierme M, Bedossa P, Farges O, Valla D, Vilgrain V, Paradis V, Degos F. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: Role of biopsy. Hepatology 2012;55:800-6. [DOI: 10.1002/hep.24746] [Cited by in Crossref: 108] [Cited by in F6Publishing: 91] [Article Influence: 12.0] [Reference Citation Analysis]
182 Terashima T, Yamashita T, Horii R, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. BMC Cancer 2016;16:338. [PMID: 27246496 DOI: 10.1186/s12885-016-2380-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
183 Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, Abraldes JG, Bosch J, Sanchez-Tapias JM, Forns X, García-Pagán JC. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Clin Gastroenterol Hepatol 2015;13:1846-1853.e1. [PMID: 25912838 DOI: 10.1016/j.cgh.2015.04.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
184 Lu LH, Zhang YF, Mu-Yan C, Kan A, Zhong XP, Mei J, Ling YH, Li SH, Shi M, Wei W, Guo RP. Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. Dig Liver Dis. 2019;51:1430-1437. [PMID: 31054962 DOI: 10.1016/j.dld.2019.04.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
185 Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M. Reply to Letter: “Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on ‘Surgical Misinterpretation’ of the BCLC Staging System”: Real Misinterpretation or Lack of Clarity Within the BCLC? Ann Surg. 2015;262:e18-e19. [PMID: 24263335 DOI: 10.1097/sla.0000000000000383] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
186 Pan T, Xie Q, Lv N, Li X, Mu L, Wu P, Zhao M. Percutaneous CT-guided Radiofrequency Ablation for Lymph Node Oligometastases from Hepatocellular Carcinoma: A Propensity Score–matching Analysis. Radiology 2017;282:259-70. [DOI: 10.1148/radiol.2016151807] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
187 Cazauran JB, Pâris L, Rousset P, Mercier F, Kepenekian V, Viste A, Passot G. Anatomy of the Right Anterior Sector of the Liver and Its Clinical Implications in Surgery. J Gastrointest Surg 2018;22:1819-31. [PMID: 29916108 DOI: 10.1007/s11605-018-3831-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One. 2014;9:e102761. [PMID: 25058587 DOI: 10.1371/journal.pone.0102761] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
189 Crocetti L, Scalise P, Bozzi E, Campani D, Rossi P, Cervelli R, Bargellini I, Ghinolfi D, De Simone P, Cioni R. Microwave Ablation of Very-Early- and Early-Stage HCC: Efficacy Evaluation by Correlation with Histology after Liver Transplantation. Cancers (Basel) 2021;13:3420. [PMID: 34298633 DOI: 10.3390/cancers13143420] [Reference Citation Analysis]
190 Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, Brancatelli G, Romano P, Craxì A, Cammà C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation: Predicting survival after TACE for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2011;34:196-204. [DOI: 10.1111/j.1365-2036.2011.04694.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
191 Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. [PMID: 23409924 DOI: 10.1186/1471-2407-13-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
192 Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S, Fumolo E, Bignulin S, Fontanini E, Cerutti A. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol. 2011;31:891-899. [PMID: 21647799 DOI: 10.1007/s10875-011-9547-1] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
193 Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010;24:725-34. [PMID: 20955973 DOI: 10.1016/j.bpg.2010.07.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
194 Ma N, Zhang X, Yu F, Gao P, Fan Q, Liu L, Liu D. Role of IFN-λs , IFN-λs related genes and the DEPDC5 gene in Hepatitis B virus-related liver disease. J Viral Hepat 2014;21:e29-38. [DOI: 10.1111/jvh.12235] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
195 Aubé C, Oberti F, Lonjon J, Pageaux G, Seror O, N'Kontchou G, Rode A, Radenne S, Cassinotto C, Vergniol J, Bricault I, Leroy V, Ronot M, Castera L, Michalak S, Esvan M, Vilgrain V; CHIC Group. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int 2017;37:1515-25. [PMID: 28346737 DOI: 10.1111/liv.13429] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
196 Chen C, Chang T, Cheng K, Su W, Yang S, Lin HH, Wu S, Lee C, Changchien C, Chen C, Sheu J, Chen D, Lu S. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int 2006;26:766-73. [DOI: 10.1111/j.1478-3231.2006.01309.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
197 Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, Bacchi Reggiani ML, Cucchetti A, Cescon M, Festi D. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. Journal of Hepatology 2019;70:440-8. [DOI: 10.1016/j.jhep.2018.10.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 20.0] [Reference Citation Analysis]
198 Khalili K, Kim TK, Jang HJ, Haider MA, Khan L, Guindi M, Sherman M. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol. 2011;54:723-728. [PMID: 21156219 DOI: 10.1016/j.jhep.2010.07.025] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 9.7] [Reference Citation Analysis]
199 Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am. 2010;90:803-816. [PMID: 20637949 DOI: 10.1016/j.suc.2010.04.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
200 Kim J, Yoon C, Seong N, Jeong S, Kim J. Fluoroscopy-guided radiofrequency ablation for small hepatocellular carcinoma: a retrospective comparison with ultrasound-guided ablation. Clinical Radiology 2015;70:1009-15. [DOI: 10.1016/j.crad.2015.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
201 Zhang Z, Ge S, Wang X, Yuan Q, Yan Q, Ye H, Che Y, Lin Y, Zhang J, Liu P. Serum miR-483-5p as a potential biomarker to detect hepatocellular carcinoma. Hepatol Int. 2013;7:199-207. [PMID: 26201634 DOI: 10.1007/s12072-012-9341-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
202 Kim JM, Hyuck C, Kwon D, Joh JW, Lee JH, Paik SW, Park CK. Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma. World J Surg. 2013;37:1371-1378. [PMID: 23443153 DOI: 10.1007/s00268-013-1966-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
203 Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS One. 2018;13:e0199760. [PMID: 29953518 DOI: 10.1371/journal.pone.0199760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
204 Wong J, Lee K, Lee P, Ho S, Yu S, Ng W, Cheung Y, Tsang Y, Ling E, Lai P. Radiofrequency Ablation for 110 Malignant Liver Tumours: Preliminary Results on Percutaneous and Surgical Approaches. Asian Journal of Surgery 2009;32:13-20. [DOI: 10.1016/s1015-9584(09)60003-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
205 Ribero D, Curley SA, Imamura H, Madoff DC, Nagorney DM, Ng KK, Donadon M, Vilgrain V, Torzilli G, Roh M, Vauthey J. Selection for Resection of Hepatocellular Carcinoma and Surgical Strategy: Indications for Resection, Evaluation of Liver Function, Portal Vein Embolization, and Resection. Ann Surg Oncol 2008;15:986-92. [DOI: 10.1245/s10434-007-9731-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
206 Brunot A, M'sadek A, Le Roy F, Duval M, Le Sourd S, Ventroux E, Crouzet L, Guillygomarc’h A, Boucher E, Lelievre N, Laguerre B, Edeline J. Les infirmières cliniciennes améliorent la gestion des toxicités des patients traités par sorafénib pour carcinome hépatocellulaire. Bulletin du Cancer 2016;103:941-8. [DOI: 10.1016/j.bulcan.2016.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
207 Thein HH, Isaranuwatchai W, Campitelli MA, Feld JJ, Yoshida E, Sherman M, Hoch JS, Peacock S, Krahn MD, Earle CC. Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology 2013;58:1375-84. [PMID: 23300063 DOI: 10.1002/hep.26231] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
208 Mancuso A. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol 2010; 2(5): 171-174 [PMID: 21160991 DOI: 10.4254/wjh.v2.i5.171] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
209 Chen VL, Le AK, Kim NG, Kim LH, Nguyen NH, Nguyen PP, Zhao C, Nguyen MH. Effects of Cirrhosis on Short-term and Long-term Survival of Patients With Hepatitis B-related Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2016;14:887-895.e1. [PMID: 26820401 DOI: 10.1016/j.cgh.2015.12.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
210 Bartolozzi C, Battaglia V, Bozzi E. Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR. Abdom Imaging 2011;36:290-9. [DOI: 10.1007/s00261-011-9687-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
211 Guan YS, Ahmad Al-Shatouri M, He Q, Liu WM. Hepatocellular carcinoma: carcinogenesis, establishment, progression, and therapies. Biomed Res Int. 2014;2014:706142. [PMID: 25028663 DOI: 10.1155/2014/239706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
212 Kim SB. Diffuse Infiltrative Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Completely Cured by Transcatheter Arterial Chemoembolization: Case Report with 8-Year Follow-Up. Case Rep Gastroenterol 2016;10:623-8. [PMID: 27920652 DOI: 10.1159/000452208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
213 Diaz-Sanchez A, Matilla A, Nuñez O, Lorente R, Fernandez A, Rincón D, Campos R, Bañares R, Clemente G. Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. Scand J Gastroenterol 2013;48:334-43. [PMID: 23249262 DOI: 10.3109/00365521.2012.746391] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
214 Lau KN, Swan RZ, Sindram D, Martinie JB, Iannitti DA. Hepatic tumor ablation: application in a community hospital setting. Surg Oncol Clin N Am 2011;20:455-66, viii. [PMID: 21640915 DOI: 10.1016/j.soc.2011.01.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
215 Farid K, Elalfy H, Abo El-Khair SM, Elgamal H, Besheer T, Elmokadem A, Shabana W, Abed S, Elegezy M, El-Khalek AA, El-Morsy A, Negm A, Elsamanoudy AZ, El Deek B, Amer T, El-Bendary M. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Expert Rev Gastroenterol Hepatol 2020;14:1203-14. [PMID: 32933325 DOI: 10.1080/17474124.2020.1823215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
216 Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, Park YS, Kang WK, Lim HY. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology. 2011;80:167-174. [PMID: 21701230 DOI: 10.1159/000327591] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
217 Zhou Z, Lai P, Zhang S, Wang Y, Qu N, Lu D, Gao L, Xu L, Yang Y, Zhang T, Sun X, Zheng X, Liu Y, Liang H, Chen S. The Relationship between Hepatic Myeloid-Derived Suppressor Cells and Clinicopathological Parameters in Patients with Chronic Liver Disease. Biomed Res Int 2021;2021:6612477. [PMID: 33860040 DOI: 10.1155/2021/6612477] [Reference Citation Analysis]
218 Izzo F, Palaia R, Albino V, Amore A, di Giacomo R, Piccirillo M, Leongito M, Nasto A, Granata V, Petrillo A, Lastoria S. Hepatocellular carcinoma and liver metastases: clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments. Infect Agent Cancer 2015;10:11. [PMID: 25897320 DOI: 10.1186/s13027-015-0006-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
219 Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health 2011;13:842-8. [PMID: 20890660 DOI: 10.1007/s10903-010-9395-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
220 Gao H, Zhang Y, Liang H, Li P, Peng Z, Pang X, Chen M. Radiofrequency Ablation Does Not Induce the Significant Increase of CD4+CD25+Foxp3+ Regulatory T Cells Compared with Surgical Resection in Hepal-6 Tumor Model. Arch Immunol Ther Exp 2013;61:333-40. [DOI: 10.1007/s00005-013-0226-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
221 Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019;25:245-63. [PMID: 30759967 DOI: 10.3350/cmh.2018.0090] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 41.0] [Reference Citation Analysis]
222 Xu D, Wang Y, Wu J, Zhang Z, Chen J, Xie M, Tang R, Chen C, Chen L, Lin S, Luo X, Zheng J. ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2/PLK1/PTEN pathway. Cell Death Dis 2021;12:162. [PMID: 33558466 DOI: 10.1038/s41419-021-03450-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
223 Lee CH, Kim KA, Lee J, Park YS, Choi JW, Park CM. Using low tube voltage (80kVp) quadruple phase liver CT for the detection of hepatocellular carcinoma: two-year experience and comparison with Gd-EOB-DTPA enhanced liver MRI. Eur J Radiol. 2012;81:e605-e611. [PMID: 22297180 DOI: 10.1016/j.ejrad.2011.12.033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
224 Suriawinata A, Thung SN. Hepatitis C virus and malignancy. Hepatol Res. 2007;37:397-401. [PMID: 17437526 DOI: 10.1111/j.1872-034X.2007.00057.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
225 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med. 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.di] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
226 Irie K, Morimoto M, Numata K, Kondo M, Moriya S, Shimoyama Y, Nozaki A, Goda Y, Kobayashi S, Ueno M, Ohkawa S, Tanaka K, Maeda S. Enhancement of radiofrequency ablation of the liver combined with transarterial embolization using various embolic agents. Abdom Imaging 2015;40:1821-8. [PMID: 25526685 DOI: 10.1007/s00261-014-0332-5] [Reference Citation Analysis]
227 Ahn DG, Kim HJ, Kang H, Lee HW, Bae SH, Lee JH, Paik YH, Lee JS. Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea. Korean J Intern Med 2016;31:46-53. [PMID: 26767857 DOI: 10.3904/kjim.2016.31.1.46] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
228 Tacher V, Lin M, Chao M, Gjesteby L, Bhagat N, Mahammedi A, Ardon R, Mory B, Geschwind JF. Semiautomatic volumetric tumor segmentation for hepatocellular carcinoma: comparison between C-arm cone beam computed tomography and MRI. Acad Radiol 2013;20:446-52. [PMID: 23498985 DOI: 10.1016/j.acra.2012.11.009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
229 Imai Y, Katayama K, Hori M, Yakushijin T, Fujimoto K, Itoh T, Igura T, Sakakibara M, Takamura M, Tsurusaki M, Takahashi H, Nakanishi K, Usuki N, Tsuji K, Ohashi H, Kim T, Takehara T, Murakami T. Prospective Comparison of Gd-EOB-DTPA-Enhanced MRI with Dynamic CT for Detecting Recurrence of HCC after Radiofrequency Ablation. Liver Cancer 2017;6:349-59. [PMID: 29234638 DOI: 10.1159/000481416] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
230 Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010;25:1426-1434. [PMID: 20659234 DOI: 10.1111/j.1440-1746.2010.06285.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
231 Boctor EM, Choti MA, Burdette EC, Webster Iii RJ. Three-dimensional ultrasound-guided robotic needle placement: an experimental evaluation. Int J Med Robot 2008;4:180-91. [PMID: 18433079 DOI: 10.1002/rcs.184] [Cited by in Crossref: 77] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
232 Fang F, Chang R, Yang L. Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer 2012;118:1782-94. [PMID: 22009757 DOI: 10.1002/cncr.26482] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 7.5] [Reference Citation Analysis]
233 Bolondi L. The appropriate allocation of CEUS in the diagnostic algorithm of liver lesions: a debated issue. Ultrasound Med Biol. 2013;39:183-185. [PMID: 23140590 DOI: 10.1016/j.ultrasmedbio.2012.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
234 Forner A, Roayaie S. Clinical research in hepatocellular carcinoma: study design and endpoints. J Hepatol. 2009;50:850-853. [PMID: 19329214 DOI: 10.1016/j.jhep.2009.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
235 Bhayana D, Kim TK, Jang HJ, Burns PN, Wilson SR. Hypervascular liver masses on contrast-enhanced ultrasound: the importance of washout. AJR Am J Roentgenol. 2010;194:977-983. [PMID: 20308500 DOI: 10.2214/ajr.09.3375] [Cited by in Crossref: 82] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
236 Cholongitas E, Burroughs AK, Dhillon AP. Liver Biopsy. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 762-70. [DOI: 10.1002/9781444314403.ch46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
237 Ni XC, Yi Y, Fu YP, He HW, Cai XY, Wang JX, Zhou J, Cheng YF, Jin JJ, Fan J, Qiu SJ. Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma. Medicine (Baltimore) 2015;94:e1486. [PMID: 26356714 DOI: 10.1097/MD.0000000000001486] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
238 Cabibbo G, Maida M, Genco C, Alessi N, Peralta M, Butera G, Galia M, Brancatelli G, Genova C, Raineri M, Orlando E, Attardo S, Giarratano A, Midiri M, Di Marco V, Craxì A, Cammà C. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One 2013;8:e70016. [PMID: 23922893 DOI: 10.1371/journal.pone.0070016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
239 Grillone A, Riva ER, Mondini A, Forte C, Calucci L, Innocenti C, de Julian Fernandez C, Cappello V, Gemmi M, Moscato S, Ronca F, Sacco R, Mattoli V, Ciofani G. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles. Adv Healthcare Mater 2015;4:1681-90. [DOI: 10.1002/adhm.201500235] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
240 Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14-22. [PMID: 21115577 DOI: 10.1634/theoncologist.2010-s4-14] [Cited by in Crossref: 293] [Cited by in F6Publishing: 163] [Article Influence: 29.3] [Reference Citation Analysis]
241 Picardi M, Soricelli A, Pane F, Zeppa P, Nicolai E, De Laurentiis M, Grimaldi F, Rotoli B. Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. Radiology. 2009;251:574-582. [PMID: 19401581 DOI: 10.1148/radiol.2512081293] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
242 Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:565-575. [PMID: 28648803 DOI: 10.1016/s2468-1253(17)30156-5] [Cited by in Crossref: 154] [Cited by in F6Publishing: 97] [Article Influence: 38.5] [Reference Citation Analysis]
243 Zhang W, Chen J, Liu L, Wang L, Liu J, Su D. Prognostic value of preoperative computed tomography in HBV-related hepatocellular carcinoma patients after curative resection. Onco Targets Ther 2019;12:3791-804. [PMID: 31190879 DOI: 10.2147/OTT.S199136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
244 Ippolito D, Bonaffini PA, Ratti L, Antolini L, Corso R, Fazio F, Sironi S. Hepatocellular carcinoma treated with transarterial chemoembolization: Dynamic perfusion-CT in the assessment of residual tumor. World J Gastroenterol 2010; 16(47): 5993-6000 [PMID: 21157976 DOI: 10.3748/wjg.v16.i47.5993] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
245 Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007;22:669-675. [PMID: 17444854 DOI: 10.1111/j.1440-1746.2007.04898.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
246 Akagi M, Nakamura Y, Higaki T, Narita K, Honda Y, Awai K. Deep learning reconstruction of equilibrium phase CT images in obese patients. Eur J Radiol 2020;133:109349. [PMID: 33152626 DOI: 10.1016/j.ejrad.2020.109349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
247 Ando Y, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Ishikawa T, Nakano I, Hirooka Y, Goto H. Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment. Hepatol Res 2018;48:E240-51. [PMID: 28865403 DOI: 10.1111/hepr.12976] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
248 Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME. Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis. Am J Gastroenterology 2007;102:2196-205. [DOI: 10.1111/j.1572-0241.2007.01405.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 6.2] [Reference Citation Analysis]
249 Verslype C, Libbrecht L. The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Practice & Research Clinical Gastroenterology 2007;21:983-96. [DOI: 10.1016/j.bpg.2007.09.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
250 Farinati F, Sergio A, Giacomin A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F; Italian Liver Cancer group. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol 2009;21:1212-8. [PMID: 19465859 DOI: 10.1097/MEG.0b013e32831a86f8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
251 Renner P, Schuhbaum J, Kroemer A, Zeman F, Loss M, Lang SA, Geissler EK, Schlitt HJ, Farkas SA. Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma. Langenbecks Arch Surg 2016;401:43-53. [DOI: 10.1007/s00423-015-1359-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
252 Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, Lleo A. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol 2019; 25(40): 6041-6052 [PMID: 31686761 DOI: 10.3748/wjg.v25.i40.6041] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
253 Mori M, Genda T, Ichida T, Murata A, Kamei M, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Ishikawa S. Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk. Hepatol Res. 2016; Epub ahead of print. [PMID: 27084455 DOI: 10.1111/hepr.12725] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
254 Moribata K, Tamai H, Shingaki N, Mori Y, Shiraki T, Enomoto S, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Ichinose M. Ultrasonogram of hepatocellular carcinoma is associated with outcome after radiofrequency ablation. World J Hepatol 2012; 4(12): 374-381 [DOI: 10.4254/wjh.v4.i12.374] [Reference Citation Analysis]
255 Marquardt JU, Nguyen-Tat M, Galle PR, Wörns MA. Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. Visc Med 2016;32:110-5. [PMID: 27413728 DOI: 10.1159/000445407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
256 Pepin K, Grimm R, Kargar S, Howe BM, Fritchie K, Frick M, Wenger D, Okuno S, Ehman R, McGee K, James S, Laack N, Herman M, Pafundi D. Soft Tissue Sarcoma Stiffness and Perfusion Evaluation by MRE and DCE-MRI for Radiation Therapy Response Assessment: A Technical Feasibility Study. Biomed Phys Eng Express 2019;5. [PMID: 32110433 DOI: 10.1088/2057-1976/ab2175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
257 Chen W, Wang M, Zhang Z, Tang H, Zuo X, Meng X, Xiong M, Zhou F, Liang B, Dai F, Fang J, Gao J, Zhu J, Zhu Y, Wan H, Wang M, Chan S, Sun L. Replication the association of 2q32.2–q32.3 and 14q32.11 with hepatocellular carcinoma. Gene 2015;561:63-7. [DOI: 10.1016/j.gene.2015.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
258 Chen CJ, Yang YH, Lin MH, Lee CP, Tsan YT, Lai MN, Yang HY, Ho WC, Chen PC; Health Data Analysis in Taiwan (hDATa) Research Group. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Int J Cancer 2018;143:1578-87. [PMID: 29667191 DOI: 10.1002/ijc.31544] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
259 Li J, Jin B, Wang T, Li W, Wang Z, Zhang H, Song Y, Li N. Serum microRNA expression profiling identifies serum biomarkers for HCV-related hepatocellular carcinoma. Cancer Biomark 2019;26:501-12. [PMID: 31658041 DOI: 10.3233/CBM-181970] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
260 Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD;  HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148. [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014] [Cited by in Crossref: 401] [Cited by in F6Publishing: 367] [Article Influence: 30.8] [Reference Citation Analysis]
261 Huang WK, Yang SF, You LN, Liu M, Liu DY, Gu P, Fan XW. Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. Contemp Oncol (Pozn) 2016;20:468-74. [PMID: 28239285 DOI: 10.5114/wo.2016.65607] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
262 Li L, Diao W, Zen K. Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:21-33. [PMID: 27508173 DOI: 10.2147/JHC.S44463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
263 Soydal C, Arslan MF, Kucuk ON, Idilman R, Bilgic S. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients. Nucl Med Commun. 2016;37:646-649. [PMID: 26905317 DOI: 10.1097/mnm.0000000000000486] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
264 Lee DH, Lee JM, Lee JY, Kim SH, Han JK, Choi BI. Radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: long-term results and prognostic factors in 168 patients with cirrhosis. Cardiovasc Intervent Radiol 2014;37:705-15. [PMID: 23912493 DOI: 10.1007/s00270-013-0708-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
265 Hoekstra LT, Wakkie T, Busch OR, Gouma DJ, Beuers U, van Gulik T. Predictors of posthepatectomy ascites with or without previous portal vein embolization. Dig Surg 2012;29:468-74. [PMID: 23296107 DOI: 10.1159/000345583] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
266 Tse EY, Ching YP. The role of p21-activated kinases in hepatocellular carcinoma metastasis. J Mol Signal 2014;9:7. [PMID: 25093037 DOI: 10.1186/1750-2187-9-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
267 Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M; on behalf of the SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology 2011;54:2055-63. [DOI: 10.1002/hep.24644] [Cited by in Crossref: 237] [Cited by in F6Publishing: 242] [Article Influence: 23.7] [Reference Citation Analysis]
268 Wong CR, Garcia RT, Trinh HN, Lam KD, Ha NB, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Dig Dis Sci. 2009;54:2712-2721. [PMID: 19876735 DOI: 10.1007/s10620-009-1015-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
269 Jou JH, Chen PH, Jazwinski A, Bouneva I, Smith AD, Muir AJ. Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. Dig Dis Sci. 2010;55:3591-3596. [PMID: 20683659 DOI: 10.1007/s10620-010-1366-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
270 Muir K, Hazim A, He Y, Peyressatre M, Kim DY, Song X, Beretta L. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res 2013;73:4722-31. [PMID: 23749645 DOI: 10.1158/0008-5472.CAN-12-3797] [Cited by in Crossref: 89] [Cited by in F6Publishing: 60] [Article Influence: 11.1] [Reference Citation Analysis]
271 Salmon-Ceron D, Nahon P, Layese R, Bourcier V, Sogni P, Bani-Sadr F, Audureau E, Merchadou L, Dabis F, Wittkop L, Roudot-Thoraval F; ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients. Hepatology 2019;70:939-54. [PMID: 30569448 DOI: 10.1002/hep.30400] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
272 Jin K, Lu M, Liu F, Gu J, Du X, Xing B. N-WASP is highly expressed in hepatocellular carcinoma and associated with poor prognosis. Surgery 2013;153:518-25. [DOI: 10.1016/j.surg.2012.08.067] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
273 Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35:765-774. [PMID: 22648700 DOI: 10.1007/s00270-012-0423-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
274 Zhong NB, Lv GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas: A clinical study. Mol Clin Oncol 2014;2:839-44. [PMID: 25054055 DOI: 10.3892/mco.2014.304] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
275 Robbins AS, Daily MF, Aoki CA, Chen MS Jr, Troppmann C, Perez RV. Decreasing disparity in liver transplantation among white and Asian patients with hepatocellular carcinoma: California, 1998-2005. Cancer. 2008;113:2173-2179. [PMID: 18792066 DOI: 10.1002/cncr.23766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
276 Baldassarre F, Vergaro V, Scarlino F, De Santis F, Lucarelli G, Torre AD, Ciccarella G, Rinaldi R, Giannelli G, Leporatti S. Polyelectrolyte Capsules as Carriers for Growth Factor Inhibitor Delivery to Hepatocellular Carcinoma: Polyelectrolyte Capsules as Carriers for Growth Factor Inhibitor Delivery …. Macromol Biosci 2012;12:656-65. [DOI: 10.1002/mabi.201100457] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
277 Yang DJ, Luo KL, Liu H, Cai B, Tao GQ, Su XF, Hou XJ, Ye F, Li XY, Tian ZQ. Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma. Oncotarget 2017;8:2960-70. [PMID: 27936465 DOI: 10.18632/oncotarget.13813] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
278 Hu F, Han J, Zhai B, Ming X, Zhuang L, Liu Y, Pan S, Liu T. Blocking autophagy enhances the apoptosis effect of bufalin on human hepatocellular carcinoma cells through endoplasmic reticulum stress and JNK activation. Apoptosis 2014;19:210-23. [PMID: 24114361 DOI: 10.1007/s10495-013-0914-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
279 Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008;2:453-62. [PMID: 19707376 DOI: 10.2147/btt.s3254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
280 Rao SX, Wang J, Wang J, Jiang XQ, Long LL, Li ZP, Li ZL, Shen W, Zhao XM, Hu DY, Zhang HM, Zhang L, Huan Y, Liang CH, Song B, Zeng MS. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoxetic acid disodium. J Dig Dis 2019;20:54-61. [PMID: 30693659 DOI: 10.1111/1751-2980.12707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
281 Zhou SJ, Deng YL, Liang HF, Jaoude JC, Liu FY. Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and Notch signaling in hepatocellular carcinoma. Cell Death Differ. 2017;24:1577-1587. [PMID: 28574502 DOI: 10.1038/cdd.2017.87] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
282 Jou J, Diehl AM. Epithelial-mesenchymal transitions and hepatocarcinogenesis. J Clin Invest. 2010;120:1031-1034. [PMID: 20335655 DOI: 10.1172/JCI42615] [Cited by in Crossref: 71] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
283 Zevin B. Managing chronic hepatitis C in primary-care settings: more than antiviral therapy. Public Health Rep 2007;122 Suppl 2:78-82. [PMID: 17542459 DOI: 10.1177/00333549071220S215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
284 Hui TC, Pua U. Arterial Portography during Transarterial Chemoembolization: Still a Necessity in the Age of Contrast-enhanced Cross-sectional Imaging? Journal of Vascular and Interventional Radiology 2014;25:41-6. [DOI: 10.1016/j.jvir.2013.10.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
285 Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB, Mulcahy MF, Omary RA, Salem R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56:1112-1120. [PMID: 22245905 DOI: 10.1016/j.jhep.2011.11.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.8] [Reference Citation Analysis]
286 Ishizawa T, Mise Y, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. Surgical technique: new advances for expanding indications and increasing safety in liver resection for HCC: the Eastern perspective. J Hepatobiliary Pancreat Sci. 2010;17:389-393. [PMID: 19924372 DOI: 10.1007/s00534-009-0231-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
287 Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. Journal of Gastroenterology and Hepatology 2010;25:129-37. [DOI: 10.1111/j.1440-1746.2009.05988.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 5.8] [Reference Citation Analysis]
288 Lee KH, Yu JI, Park HC, Park SY, Shin JS, Shin EH, Cho S, Jung SH, Han YY, Lim DH. Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma? Radiat Oncol J. 2018;36:129-138. [PMID: 29983033 DOI: 10.3857/roj.2017.00598] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
289 Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M, Stein K. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98:1166-1175. [PMID: 18382459 DOI: 10.1038/sj.bjc.6604301] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 5.7] [Reference Citation Analysis]
290 Fernandes ML, Lin CC, Lin CJ, Chen WT, Lin SM. Prospective study of a 'popping' sound during percutaneous radiofrequency ablation for hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21:237-244. [PMID: 20031448 DOI: 10.1016/j.jvir.2009.10.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
291 Kim BK, Kim KA, An C, Yoo EJ, Park JY, Kim DY, Ahn SH, Han KH, Kim SU, Kim MJ. Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. Liver Int 2015;35:1722-30. [PMID: 25444138 DOI: 10.1111/liv.12751] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
292 Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X, Han G. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One. 2014;9:e91124. [PMID: 24651044 DOI: 10.1371/journal.pone.0091124] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
293 Chen X, Wu W, Ding J. Aberrant TIG1 methylation associated with its decreased expression and clinicopathological significance in hepatocellular carcinoma. Tumor Biol 2014;35:967-71. [DOI: 10.1007/s13277-013-1129-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
294 Hassany SM, Moustafa EFA, Taher ME, Abdeltwab AA, Blum HE. Screening for hepatocellular carcinoma by Egyptian physicians. World J Gastrointest Oncol 2015; 7(9): 161-171 [PMID: 26380060 DOI: 10.4251/wjgo.v7.i9.161] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
295 Lei JW, Ji XY, Hong JF, Li WB, Chen Y, Pan Y, Guo J. Prediction of posthepatectomy liver failure using transient elastography in patients with hepatitis B related hepatocellular carcinoma. BMC Gastroenterol 2017;17:171. [PMID: 29284411 DOI: 10.1186/s12876-017-0732-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
296 Mani D, Aboulafia DM. Screening guidelines for non-AIDS defining cancers in HIV-infected individuals. Curr Opin Oncol 2013;25:518-25. [PMID: 23942295 DOI: 10.1097/CCO.0b013e328363e04a] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
297 Forner A, Bruix J. Ablation for hepatocellular carcinoma: Is there need to have a winning technique? J Hepatol. 2010;52:310-312. [PMID: 20133005 DOI: 10.1016/j.jhep.2009.11.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
298 Falleti E, Cmet S, Fabris C, Bitetto D, Cussigh A, Fornasiere E, Bignulin E, Feruglio C, Mosanghini E, Fontanini E, Pirisi M, Toniutto P. Association between the epidermal growth factor rs4444903 G/G genotype and advanced fibrosis at a young age in chronic hepatitis C. Cytokine 2012;57:68-73. [PMID: 22122913 DOI: 10.1016/j.cyto.2011.10.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
299 Chen S, Zhang K, Liu W, Yu W. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study. Eur J Cancer 2020;134:90-8. [PMID: 32497895 DOI: 10.1016/j.ejca.2020.03.032] [Reference Citation Analysis]
300 Josephs DH, Ross PJ. Sorafenib in hepatocellular carcinoma. British Journal of Hospital Medicine 2010;71:451-6. [DOI: 10.12968/hmed.2010.71.8.77669] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
301 Ding H, Su M, Zhu C, Wang L, Zheng Q, Wan Y. CT-guided versus laparoscopic radiofrequency ablation in recurrent small hepatocellular carcinoma against the diaphragmatic dome. Sci Rep 2017;7:44583. [PMID: 28291254 DOI: 10.1038/srep44583] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
302 Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol. 2013;9:845-854. [PMID: 23718305 DOI: 10.2217/fon.13.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
303 Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. [PMID: 19330875 DOI: 10.1002/hep.22759] [Cited by in Crossref: 2134] [Cited by in F6Publishing: 1938] [Article Influence: 177.8] [Reference Citation Analysis]
304 Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis. Journal of Hepatology 2006;45:127-43. [DOI: 10.1016/j.jhep.2006.05.001] [Cited by in Crossref: 129] [Cited by in F6Publishing: 110] [Article Influence: 8.6] [Reference Citation Analysis]
305 Vilana R, Forner A, García Á, Ayuso C, Bru C. Carcinoma hepatocelular: diagnóstico, estadificación y estrategia terapéutica. Radiología 2010;52:385-98. [DOI: 10.1016/j.rx.2010.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
306 Hiraoka A, Kumada T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M. What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure? Liver Cancer 2021;10:115-25. [PMID: 33977088 DOI: 10.1159/000513355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
307 Abdel-Wahab R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, Kaseb AO. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:131-42. [PMID: 27508202 DOI: 10.2147/JHC.S81309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
308 Nishikawa H, Osaki Y. Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis. Mediators Inflamm. 2015;2015:872152. [PMID: 26494949 DOI: 10.1155/2015/872152] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
309 Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31:3647-3655. [PMID: 24002499 DOI: 10.1200/jco.2012.48.5896] [Cited by in Crossref: 158] [Cited by in F6Publishing: 82] [Article Influence: 19.8] [Reference Citation Analysis]
310 Jang JW, Chun JY, Park YM, Shin SK, Yoo W, Kim SO, Hong SP. Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci 2012;103:296-304. [PMID: 22136288 DOI: 10.1111/j.1349-7006.2011.02170.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
311 Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D’Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol. 2012;56:855-861. [PMID: 22178270 DOI: 10.1016/j.jhep.2011.11.017] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 9.3] [Reference Citation Analysis]
312 Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol 2007;41:777-82. [PMID: 17700427 DOI: 10.1097/MCG.0b013e3180381560] [Cited by in Crossref: 89] [Cited by in F6Publishing: 56] [Article Influence: 6.4] [Reference Citation Analysis]
313 Xu HX, Wang Y, Lu MD, Liu LN. Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol. 2012;85:1078-1084. [PMID: 22374282 DOI: 10.1259/bjr/24563774] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
314 Hoekstra LT, Bieze M, Busch OR, Gouma DJ, van Gulik TM. Staging laparoscopy in patients with hepatocellular carcinoma: is it useful? Surg Endosc 2013;27:826-31. [PMID: 23052500 DOI: 10.1007/s00464-012-2519-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
315 Goh BK, Chow PK, Teo JY, Wong JS, Chan CY, Cheow PC, Chung AY, Ooi LL. Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma. J Gastrointest Surg. 2014;18:1477-1485. [PMID: 24855028 DOI: 10.1007/s11605-014-2542-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
316 Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol. 2012;227:2947-2952. [PMID: 21959795 DOI: 10.1002/jcp.23041] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
317 Habbel VSA, Zeile M, Stavrou GA, Wacker F, Brüning R, Oldhafer KJ, Rodt T. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:3463-79. [PMID: 31332502 DOI: 10.1007/s00261-019-02128-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
318 Brode SK, Ling SC, Chapman KR. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. CMAJ 2012;184:1365-71. [PMID: 22761482 DOI: 10.1503/cmaj.111749] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
319 Zhao C, Nguyen MH. Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life Practice. J Clin Gastroenterol. 2016;50:120-133. [PMID: 26583266 DOI: 10.1097/mcg.0000000000000446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
320 Peng ZW, Liang HH, Chen MS, Zhang YJ, Zhang YQ, Lau WY. Conformal radiofrequency ablation of hepatocellular carcinoma with a multi-pin bipolar system. J Surg Oncol. 2011;103:69-74. [PMID: 21031425 DOI: 10.1002/jso.21742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
321 Wu K, Shui Y, Sun W, Lin S, Pang H. Utility of Radiomics for Predicting Patient Survival in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With Stereotactic Body Radiotherapy. Front Oncol 2020;10:569435. [PMID: 33178598 DOI: 10.3389/fonc.2020.569435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
322 Latteri F, Sandonato L, Di Marco V, Parisi P, Cabibbo G, Lombardo G, Galia M, Midiri M, Latteri MA, Craxì A. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig Liver Dis. 2008;40:684-689. [PMID: 18294940 DOI: 10.1016/j.dld.2007.12.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
323 Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M. Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability. Hepatol Res 2020;50:67-74. [PMID: 31301213 DOI: 10.1111/hepr.13407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
324 Chon YE, Jung ES, Park JY, Kim DY, Ahn SH, Han KH, Chon CY, Jung KS, Kim SU. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol. 2012;46:518-525. [PMID: 22688146 DOI: 10.1097/mcg.0b013e31825079f1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
325 Jang JW, Song Y, Kim KM, Kim JS, Choi EK, Kim J, Seo H. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes. BMC Cancer 2016;16:810. [PMID: 27756242 DOI: 10.1186/s12885-016-2816-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
326 Lee HS, Park JJ, Kim SU, Lee JE, Leem GL, Kim Y, Kim BK, Park JY, Kim DY, Ahn SH, Han KH. Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. Scand J Gastroenterol 2016;51:618-24. [PMID: 26653394 DOI: 10.3109/00365521.2015.1121513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
327 Wiencke K, Boberg K. Current consensus on the management of primary sclerosing cholangitis. Clinics and Research in Hepatology and Gastroenterology 2011;35:786-91. [DOI: 10.1016/j.clinre.2011.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
328 Scartozzi M, Faloppi L, Bianconi M, Giampieri R, Maccaroni E, Bittoni A, Del Prete M, Loretelli C, Belvederesi L, Svegliati Baroni G. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One. 2012;7:e32653. [PMID: 22461886 DOI: 10.1371/journal.pone.0032653] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
329 Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016; 22(15): 4034-4040 [PMID: 27099447 DOI: 10.3748/wjg.v22.i15.4034] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
330 Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Ito T. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015;30:1183-1189. [PMID: 25678094 DOI: 10.1111/jgh.12915] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 11.6] [Reference Citation Analysis]
331 Zhong-yi Z, Wei Y, Kun Y, Ying D, Wei W, Jung-chieh L, Min-hua C. Needle track seeding after percutaneous radiofrequency ablation of hepatocellular carcinoma: 14-year experience at a single centre. International Journal of Hyperthermia 2016;33:454-8. [DOI: 10.1080/02656736.2017.1278630] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
332 Zhu Y, Xu D, Zhang Z, Dong J, Zhou Y, Zhang WW, Hong L, Zhu WW. A new laboratory-based algorithm to predict microvascular invasion and survival in patients with hepatocellular carcinoma. Int J Surg. 2018;57:45-53. [PMID: 30075291 DOI: 10.1016/j.ijsu.2018.07.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
333 Itokawa N, Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Kondo C, Iwakiri K. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. Int J Clin Oncol 2016;21:676-83. [PMID: 26701173 DOI: 10.1007/s10147-015-0942-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
334 Woo GA, O'Brien C. Long-term management of alcoholic liver disease. Clin Liver Dis 2012;16:763-81. [PMID: 23101981 DOI: 10.1016/j.cld.2012.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
335 Wu Q, Zhang H, Chen M, Zhang Y, Huang J, Xu Z, Wang W. Preparation of carbon-coated iron nanofluid and its application in radiofrequency ablation: Application of Fe@C Nanofluids in Radiofrequency Ablation. J Biomed Mater Res 2015;103:908-14. [DOI: 10.1002/jbm.b.33275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
336 Chang CJ, Hou MC, Tseng HS, Liao WC, Lin HC, Lee SD. Bleeding gastric ulcer after prophylactic coiling of transarterial chemoembolization. J Clin Gastroenterol 2010;44:588-91. [PMID: 20453659 DOI: 10.1097/MCG.0b013e3181d9eff3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
337 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD;  American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49:1017-1044. [PMID: 19243014 DOI: 10.1002/hep.22742] [Cited by in Crossref: 1217] [Cited by in F6Publishing: 1043] [Article Influence: 101.4] [Reference Citation Analysis]
338 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 4.3] [Reference Citation Analysis]
339 Qu JR, Li HL, Shao NN, Li X, Yan GL, Zhang HK, Luo JP, Zhang SN, Li YL, Liu CC. Additional diffusion-weighted imaging in the detection of new, very small hepatocellular carcinoma lesions after interventional therapy compared with conventional 3 T MRI alone. Clin Radiol 2012;67:669-74. [PMID: 22336669 DOI: 10.1016/j.crad.2011.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
340 Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clin Liver Dis. 2015;19:309-323. [PMID: 25921665 DOI: 10.1016/j.cld.2015.01.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
341 Lang H, Broelsch CE. [Liver resection and transplantation for hepatic tumors]. Internist (Berl) 2007;48:30-9. [PMID: 17195060 DOI: 10.1007/s00108-006-1780-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
342 Addley HC, Griffin N, Shaw AS, Mannelli L, Parker RA, Aitken S, Wood H, Davies S, Alexander GJ, Lomas DJ. Accuracy of hepatocellular carcinoma detection on multidetector CT in a transplant liver population with explant liver correlation. Clin Radiol. 2011;66:349-356. [PMID: 21295772 DOI: 10.1016/j.crad.2010.11.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
343 Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, Kudo M, Imanaka K, Kora S. A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Eur J Cancer. 2013;49:2832-2840. [PMID: 23764238 DOI: 10.1016/j.ejca.2013.05.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
344 Ismail MM, Morsi HK, Abdulateef NA, Noaman MK, Abou El-Ella GA. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance. Scand J Clin Lab Invest 2017;77:175-83. [PMID: 28276727 DOI: 10.1080/00365513.2017.1286684] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
345 Kang TW, Rhim H, Song KD, Lee MW, Cha DI, Ha SY, Ahn JH. Radiofrequency Ablation of Hepatocellular Carcinoma with a "Nodule-in-Nodule" Appearance: Long-Term Follow-up and Clinical Implications. Cardiovasc Intervent Radiol 2017;40:401-9. [PMID: 27933377 DOI: 10.1007/s00270-016-1525-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
346 Zhang YF, Wei W, Wang JH, Xu L, Jian PE, Xiao CZ, Zhong XP, Shi M, Guo RP. Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Onco Targets Ther 2016;9:4239-46. [PMID: 27471398 DOI: 10.2147/OTT.S106659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
347 Yoon YS, Han HS, Cho JY, Yoon CJ, Kim JH. Laparoscopic approach for treatment of multiple hepatocellular carcinomas. Surg Endosc. 2012;26:3133-3140. [PMID: 22538699 DOI: 10.1007/s00464-012-2304-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
348 Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, Ahn SH. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011;47:2568-2575. [PMID: 21835608 DOI: 10.1016/j.ejca.2011.07.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
349 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3521] [Article Influence: 404.7] [Reference Citation Analysis]
350 Liu W, Ma N, Gao X, Liu W, Jia J, Tang L, Li M, Yang L, Li T, Yan L, Zhang X, Yu F. Role of GSPT1 and GSPT2 polymorphisms in different outcomes upon Hepatitis B virus infection and prognosis to lamivudine therapy. Biosci Rep 2019;39:BSR20181668. [PMID: 30867251 DOI: 10.1042/BSR20181668] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
351 Bittermann T, Dwinnells K, Chadha S, Wolf MS, Olthoff KM, Serper M. Low Health Literacy Is Associated With Frailty and Reduced Likelihood of Liver Transplant Listing: A Prospective Cohort Study. Liver Transpl 2020;26:1409-21. [PMID: 32567232 DOI: 10.1002/lt.25830] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
352 Yoon SH, Lee JM, So YH, Hong SH, Kim SJ, Han JK, Choi BI. Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol. 2009;193:W482-W489. [PMID: 19933622 DOI: 10.2214/ajr.08.1818] [Cited by in Crossref: 85] [Cited by in F6Publishing: 36] [Article Influence: 7.7] [Reference Citation Analysis]
353 Sapisochin G, Castells L, Dopazo C, Bilbao I, Minguez B, Lázaro JL, Allende H, Balsells J, Caralt M, Charco R. Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis. Ann Surg Oncol. 2013;20:1194-1202. [PMID: 22965574 DOI: 10.1245/s10434-012-2655-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
354 Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 2011;41:405-16. [PMID: 21435126 DOI: 10.1111/j.1872-034X.2011.00785.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
355 Shiha G, Mousa N, Soliman R, Nnh Mikhail N, Adel Elbasiony M, Khattab M. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. J Viral Hepat 2020;27:671-9. [PMID: 32050037 DOI: 10.1111/jvh.13276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
356 Cassim S, Bilodeau M, Vincent C, Lapierre P. Novel Immunotherapies for Autoimmune Hepatitis. Front Pediatr 2017;5:8. [PMID: 28184367 DOI: 10.3389/fped.2017.00008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
357 Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. Eur J Radiol. 2013;82:e205-e211. [PMID: 23273822 DOI: 10.1016/j.ejrad.2012.12.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 7.2] [Reference Citation Analysis]
358 Xiao H, Li JL, Chen SL, Tang MM, Zhou Q, Wu TF, Li X, Peng ZW, Feng ST, Peng S, Kuang M. A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. Front Oncol 2021;11:569515. [PMID: 33718130 DOI: 10.3389/fonc.2021.569515] [Reference Citation Analysis]
359 Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C, Steuterman S, Pockros P, Frenette C. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol 2015;6:469-78. [PMID: 26487939 DOI: 10.3978/j.issn.2078-6891.2015.056] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
360 Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer. 2012;1:62-70. [PMID: 24159574 DOI: 10.1159/000342402] [Cited by in Crossref: 39] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
361 Ierardi AM, Angileri SA, Patella F, Panella S, Lucchina N, Petre EN, Pinto A, Franceschelli G, Carrafiello G, Cornalba G, Sofocleous CT. The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. Med Oncol 2017;34:11. [PMID: 28008570 DOI: 10.1007/s12032-016-0866-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
362 Huo T, Hsia C, Chu C, Huang Y, Lui W, Wu J, Lee P, Chi C, Lee S. The predictive ability of serum α-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance. J Surg Oncol 2007;95:645-51. [DOI: 10.1002/jso.20653] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
363 Iizuka N, Oka M, Sakaida I, Moribe T, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. Clin Chim Acta. 2011;412:152-158. [PMID: 20883676 DOI: 10.1016/j.cca.2010.09.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
364 Chen N, Motosugi U, Sano K, Ichikawa T, Nakano M, Morisaka H, Ichikawa S, Matsuda M, Fujii H, Enomoto N, Araki T. Early hepatocellular carcinomas showing isointensity or hyperintensity in gadoxetic acid-enhanced, hepatocyte-phase magnetic resonance images. J Comput Assist Tomogr 2013;37:466-9. [PMID: 23674023 DOI: 10.1097/RCT.0b013e3182873799] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
365 Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Yamao J, Fujimoto M, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Uejima M, Uemura M, Fukui H. Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. Oncol Rep 2013;30:545-52. [PMID: 23708326 DOI: 10.3892/or.2013.2497] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
366 Yu NC, Chaudhari V, Raman SS, Lassman C, Tong MJ, Busuttil RW, Lu DS. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:161-167. [PMID: 20920597 DOI: 10.1016/j.cgh.2010.09.017] [Cited by in Crossref: 143] [Cited by in F6Publishing: 135] [Article Influence: 13.0] [Reference Citation Analysis]
367 Schütte K, Kipper M, Kahl S, Bornschein J, Götze T, Adolf D, Arend J, Seidensticker R, Lippert H, Ricke J. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion. 2013;87:147-159. [PMID: 23548687 DOI: 10.1159/000346743] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
368 Borie F, Bouvier AM, Herrero A, Faivre J, Launoy G, Delafosse P, Velten M, Buemi A, Peng J, Grosclaude P, Trétarre B. Treatment and prognosis of hepatocellular carcinoma: a population based study in France. J Surg Oncol 2008;98:505-9. [PMID: 18932235 DOI: 10.1002/jso.21159] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
369 Sorrentino P, Tarantino L, D’Angelo S, Terracciano L, Ferbo U, Bracigliano A, Panico L, De Chiara G, Lepore M, De Stefano N. Validation of an extension of the international non-invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis. J Gastroenterol Hepatol. 2011;26:669-677. [PMID: 21054520 DOI: 10.1111/j.1440-1746.2010.06564.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
370 Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. PLoS One 2015;10:e0138907. [PMID: 26398404 DOI: 10.1371/journal.pone.0138907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
371 Wang Q, Luan W, Villanueva GA, Rahbari NN, Yee HT, Manizate F, Hiotis SP. Clinical prognostic variables in young patients (under 40 years) with hepatitis B virus-associated hepatocellular carcinoma. J Dig Dis 2012;13:214-8. [PMID: 22435506 DOI: 10.1111/j.1751-2980.2012.00577.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
372 Muaddi H, Al-Adra DP, Beecroft R, Ghanekar A, Moulton CA, Doyle A, Selzner M, Wei A, McGilvray ID, Gallinger S, Grant DR, Cattral MS, Greig PD, Kachura J, Cleary SP, Sapisochin G. Liver Transplantation is Equally Effective as a Salvage Therapy for Patients with Hepatocellular Carcinoma Recurrence Following Radiofrequency Ablation or Liver Resection with Curative Intent. Ann Surg Oncol. 2018;25:991-999. [PMID: 29327179 DOI: 10.1245/s10434-017-6329-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
373 Falade-Nwulia O, Thio CL. Liver disease, HIV and aging. Sex Health 2011;8:512-20. [PMID: 22127037 DOI: 10.1071/SH10163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
374 Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatology Research 2007;37:S178-92. [DOI: 10.1111/j.1872-034x.2007.00183.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
375 Xu L, Peng ZW, Chen MS, Shi M, Zhang YJ, Guo RP, Lin XJ, Lau WY. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. J Hepatol. 2015;63:122-130. [PMID: 25725438 DOI: 10.1016/j.jhep.2015.02.034] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 11.7] [Reference Citation Analysis]
376 Zhang Y, Fan W, Wang Y, Lu L, Fu S, Yang J, Huang Y, Yao W, Li J. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. Oncologist. 2015;20:1417-1424. [PMID: 26446238 DOI: 10.1634/theoncologist.2015-0196] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
377 Lencioni R, Crocetti L. Radiofrequency Ablation of Liver Cancer. Techniques in Vascular and Interventional Radiology 2007;10:38-46. [DOI: 10.1053/j.tvir.2007.08.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
378 Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK Jr, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968-1977. [PMID: 25689978 DOI: 10.1002/hep.27752] [Cited by in Crossref: 217] [Cited by in F6Publishing: 178] [Article Influence: 36.2] [Reference Citation Analysis]
379 Suzuki K, Okuda Y, Ota M, Kojima F, Horimoto M. Diagnosis of Hepatocellular Carcinoma Nodules in Patients With Chronic Liver Disease Using Contrast-Enhanced Sonography: Usefulness of the Combination of Arterial- and Kupffer-Phase Enhancement Patterns. Journal of Ultrasound in Medicine 2015;34:423-33. [DOI: 10.7863/ultra.34.3.423] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
380 Lee DH, Lee JY, Han JK. Superb microvascular imaging technology for ultrasound examinations: Initial experiences for hepatic tumors. Eur J Radiol. 2016;85:2090-2095. [PMID: 27776663 DOI: 10.1016/j.ejrad.2016.09.026] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
381 Zhao X, Fu J, Xu A, Yu L, Zhu J, Dai R, Su B, Luo T, Li N, Qin W, Wang B, Jiang J, Li S, Chen Y, Wang H. Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway. Cell Death Dis 2015;6:e1751. [PMID: 25950481 DOI: 10.1038/cddis.2015.120] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
382 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
383 Al-Qahtani A, Khalak HG, Alkuraya FS, Al-hamoudi W, Alswat K, Al Balwi MA, Al Abdulkareem I, Sanai FM, Abdo AA. Genome-wide association study of chronic hepatitis B virus infection reveals a novel candidate risk allele on 11q22.3. J Med Genet. 2013;50:725-732. [PMID: 24065354 DOI: 10.1136/jmedgenet-2013-101724] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
384 Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol 2016;14:151. [PMID: 27215576 DOI: 10.1186/s12957-016-0903-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
385 Sood A, Midha V, Goyal O, Goyal P, Sood N, Sharma SK. Profile of hepatocellular carcinoma in a tertiary care hospital in Punjab in northern India. Indian J Gastroenterol 2014;33:35-40. [DOI: 10.1007/s12664-013-0373-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
386 Cabibbo G, Craxì A. Needle track seeding following percutaneous procedures for hepatocellular carcinoma. World J Hepatol 2009; 1(1): 62-66 [PMID: 21160966 DOI: 10.4254/wjh.v1.i1.62] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
387 Zhang YF, Wei W, Guo ZX, Wang JH, Shi M, Guo RP. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Jpn J Clin Oncol. 2015;45:837-843. [PMID: 26079139 DOI: 10.1093/jjco/hyv089] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
388 Huwart L, Sempoux C, Salameh N, Jamart J, Annet L, Sinkus R, Peeters F, ter Beek LC, Horsmans Y, Van Beers BE. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology. 2007;245:458-466. [PMID: 17940304 DOI: 10.1148/radiol.2452061673] [Cited by in Crossref: 297] [Cited by in F6Publishing: 261] [Article Influence: 21.2] [Reference Citation Analysis]
389 Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract. 2010;64:1034-1041. [PMID: 20642705 DOI: 10.1111/j.1742-1241.2010.02414.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
390 Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB. Liver Imaging Reporting and Data System: an expert consensus statement.J Hepatocell Carcinoma. 2017;4:29-39. [PMID: 28255543 DOI: 10.2147/JHC.S125396] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
391 Lin H, Jiao X, Yu B, Du J, Xu H, Dong A, Wan C. Clinical significance of serum 14-3-3 beta in patients with hepatocellular carcinoma. CBM 2017;20:143-50. [DOI: 10.3233/cbm-160533] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
392 Rastogi A, Maiwall R, Bihari C, Ahuja A, Kumar A, Singh T, Wani ZA, Sarin SK. Cirrhosis histology and Laennec staging system correlate with high portal pressure. Histopathology. 2013;62:731-741. [PMID: 23470026 DOI: 10.1111/his.12070] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
393 Zhou P, Liang P, Dong B, Yu X, Han X, Wang Y, Han Z. Long-term results of a phase II clinical trial of superantigen therapy with staphylococcal enterotoxin C after microwave ablation in hepatocellular carcinoma. International Journal of Hyperthermia 2011;27:132-9. [DOI: 10.3109/02656736.2010.506670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
394 Becker-Weidman DJ, Kalb B, Sharma P, Kitajima HD, Lurie CR, Chen Z, Spivey JR, Knechtle SJ, Hanish SI, Adsay NV. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements. Radiology. 2011;261:824-833. [PMID: 21969663 DOI: 10.1148/radiol.11110157] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
395 Carr BI, Kanke F, Wise M, Satomura S. Clinical Evaluation of Lens Culinaris Agglutinin-Reactive α-Fetoprotein and Des-γ-Carboxy Prothrombin in Histologically Proven Hepatocellular Carcinoma in the United States. Dig Dis Sci 2007;52:776-82. [DOI: 10.1007/s10620-006-9541-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 6.1] [Reference Citation Analysis]
396 Andreana L, Isgrò G, Marelli L, Davies N, Yu D, Navalkissoor S, Burroughs AK. Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: trans-arterial radio-embolisation of HCC. Cancer Treat Rev. 2012;38:641-649. [PMID: 22169503 DOI: 10.1016/j.ctrv.2011.11.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
397 Brunot A, Le Roy F, Le Sourd S, M’sadek A, Duval M, Crouzet L, Guillygomarc’h A, Boucher E, Laguerre B, Edeline J. Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib’s Toxicities in Hepatocellular Carcinoma. Cancer Nurs 2018;41:418-23. [DOI: 10.1097/ncc.0000000000000521] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
398 Kim HY, Park JW, Joo J, Jung SJ, An S, Woo SM, Kim HB, Koh YH, Lee WJ, Kim CM. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1051-1056. [PMID: 22098152 DOI: 10.1111/j.1440-1746.2011.06963.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
399 Kim DY, Song KJ, Kim SU, Yoo EJ, Park JY, Ahn SH, Han KH. Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. Onco Targets Ther. 2013;6:1463-1469. [PMID: 24204161 DOI: 10.2147/ott.s51986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
400 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-11012-10233-11910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
401 Shim JH, Kim KM, Lee YJ, Ko GY, Yoon HK, Sung KB, Park KM, Lee SG, Lim YS, Lee HC. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2010;17:869-877. [PMID: 20033326 DOI: 10.1245/s10434-009-0788-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
402 Fuks D, Cauchy F, Fusco G, Paradis V, Durand F, Belghiti J. Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. Journal of Hepatology 2014;61:589-93. [DOI: 10.1016/j.jhep.2014.04.046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
403 Zhao P, Yang X, Qi S, Liu H, Jiang H, Hoppmann S, Cao Q, Chua MS, So SK, Cheng Z. Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes. Biomed Res Int 2013;2013:759057. [PMID: 23710458 DOI: 10.1155/2013/759057] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
404 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med 2012;4:381-6. [PMID: 23181103 DOI: 10.3892/etm.2012.611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
405 Chan SL, Wong AM, Lee K, Wong N, Chan AK. Personalized therapy for hepatocellular carcinoma: Where are we now? Cancer Treatment Reviews 2016;45:77-86. [DOI: 10.1016/j.ctrv.2016.02.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
406 Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, Cmet S, Fornasiere E, Fumolo E, Fangazio S. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54:716-722. [PMID: 21146242 DOI: 10.1016/j.jhep.2010.07.019] [Cited by in Crossref: 121] [Cited by in F6Publishing: 127] [Article Influence: 11.0] [Reference Citation Analysis]
407 Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol. 2009;44 Suppl 19:96-101. [PMID: 19148801 DOI: 10.1007/s00535-008-2258-6] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 11.3] [Reference Citation Analysis]
408 Balci NC, Befeler AS, Leiva P, Pilgram TK, Havlioglu N. Imaging of liver disease: comparison between quadruple-phase multidetector computed tomography and magnetic resonance imaging. J Gastroenterol Hepatol 2008;23:1520-7. [PMID: 18713303 DOI: 10.1111/j.1440-1746.2008.05434.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
409 op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One. 2012;7:e45066. [PMID: 23071507 DOI: 10.1371/journal.pone.0045066] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
410 Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:1886-1893.e5. [PMID: 30557738 DOI: 10.1016/j.cgh.2018.12.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
411 Mawardi M, Al-Judaibi B, Marotta P. Hepatic metastasis from adrenocortical carcinoma fifteen years after primary resection. Saudi J Gastroenterol 2012;18:140-2. [PMID: 22421721 DOI: 10.4103/1319-3767.93821] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
412 Kim SR, Ando K, Mita K, Fuki S, Ikawa H, Kanbara Y, Imoto S, Matsuoka T, Hayashi Y, Kudo M. Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cm. Oncology 2007;72 Suppl 1:58-66. [PMID: 18087183 DOI: 10.1159/000111708] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
413 Francica G, Saviano A, De Sio I, De Matthaeis N, Brunello F, Cantamessa A, Giorgio A, Scognamiglio U, Fornari F, Giangregorio F, Piscaglia F, Gualandi S, Caturelli E, Roselli P, Rapaccini GL, Pompili M. Long-term effectiveness of radiofrequency ablation for solitary small hepatocellular carcinoma: a retrospective analysis of 363 patients. Dig Liver Dis. 2013;45:336-341. [PMID: 23245589 DOI: 10.1016/j.dld.2012.10.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
414 Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013;7:87-102. [PMID: 23761989 DOI: 10.4137/CMO.S7633] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
415 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2013;2:93-107. [PMID: 24159601 DOI: 10.1159/000343845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
416 Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143-1152. [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 6.4] [Reference Citation Analysis]
417 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
418 Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250:466-473. [PMID: 19188315 DOI: 10.1148/radiol.2502072222] [Cited by in Crossref: 144] [Cited by in F6Publishing: 137] [Article Influence: 12.0] [Reference Citation Analysis]
419 Chung GE, Kim W, Lee JH, Kim YJ, Yoon JH, Lee JM, Lee JY, Kim SH, Kim D, Lee HS. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy. J Gastroenterol Hepatol. 2011;26:1638-1645. [PMID: 22011297 DOI: 10.1111/j.1440-1746.2011.06777.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
420 Canavan C, Eisenburg J, Meng L, Corey K, Hur C. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013;58:2691-704. [PMID: 23720196 DOI: 10.1007/s10620-013-2705-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
421 Gonçalves PL, Zago-Gomes Mda P, Marques CC, Mendonça AT, Gonçalves CS, Pereira FE. Etiology of liver cirrhosis in Brazil: chronic alcoholism and hepatitis viruses in liver cirrhosis diagnosed in the state of Espírito Santo. Clinics (Sao Paulo) 2013;68:291-5. [PMID: 23644846 DOI: 10.6061/clinics/2013(03)oa02] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
422 Park Y, Kim YS, Rhim H, Lim HK, Choi D, Lee WJ. Arterial enhancement of hepatocellular carcinoma before radiofrequency ablation as a predictor of postablation local tumor progression. AJR Am J Roentgenol. 2009;193:757-763. [PMID: 19696290 DOI: 10.2214/ajr.08.2202] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
423 Zhao H, Li J, Li S, Wang Y, Zhou J, Liu L, Wang C. Comparative Analysis of Presentation and Outcome After Liver Resection of Patients With Hepatocellular Carcinoma With and Without HIV. J Acquir Immune Defic Syndr 2021;86:361-8. [PMID: 33165126 DOI: 10.1097/QAI.0000000000002561] [Reference Citation Analysis]
424 Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009;15:526-32. [PMID: 20010173 DOI: 10.1097/PPO.0b013e3181c5214b] [Cited by in Crossref: 88] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
425 Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011;33:1273-1291. [PMID: 21501198 DOI: 10.1111/j.1365-2036.2011.04658.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
426 Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim do Y. Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. J Nucl Med. 2016;57:509-516. [PMID: 26742711 DOI: 10.2967/jnumed.115.167338] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
427 Pupulim LF, Felce-Dachez M, Paradis V, Vullierme MP, Zappa M, Bedossa P, Vilgrain V. Algorithm for immediate cytologic diagnosis of hepatic tumors. AJR Am J Roentgenol. 2008;190:W208-W212. [PMID: 18287414 DOI: 10.2214/AJR.07.2549] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
428 Wang M, Fu F, Zheng B, Bai Y, Wu Q, Wu J, Sun L, Liu Q, Liu M, Yang Y, Shen H, Kong D, Ma X, You P, Li X, Tian F. Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data. Br J Cancer 2021. [PMID: 34365472 DOI: 10.1038/s41416-021-01511-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
429 Zhu M, Li W, Dong X, Chen Y, Lu Y, Lin B, Guo J, Li M. Benzyl-isothiocyanate Induces Apoptosis and Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells in vitro. J Cancer 2017;8:240-8. [PMID: 28243328 DOI: 10.7150/jca.16402] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
430 Lencioni R, Crocetti L, Della Pina MC, Cioni D. Guidelines for imaging focal lesions in liver cirrhosis. Expert Review of Gastroenterology & Hepatology 2014;2:697-703. [DOI: 10.1586/17474124.2.5.697] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
431 Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016;263:1112-1125. [PMID: 26813914 DOI: 10.1097/sla.0000000000001556] [Cited by in Crossref: 124] [Cited by in F6Publishing: 87] [Article Influence: 31.0] [Reference Citation Analysis]
432 Yang T, Zhang J, Lu JH, Yang LQ, Yang GS, Wu MC, Yu WF. A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol. 2011;137:739-750. [PMID: 20607551 DOI: 10.1007/s00432-010-0935-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
433 Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer. 2012;1:94-109. [PMID: 24159577 DOI: 10.1159/000342404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
434 Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. Hepatology Research 2007;37:S230-7. [DOI: 10.1111/j.1872-034x.2007.00190.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
435 Lee JM, Zech CJ, Bolondi L, Jonas E, Kim MJ, Matsui O, Merkle EM, Sakamoto M, Choi BI. Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol. 2011;12:403-415. [PMID: 21852900 DOI: 10.3348/kjr.2011.12.4.403] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
436 Hu Y, Chen T, Chau G, Yang T, Liu C, Chen M, Chang PM, Chen T, Hsiao M, Huang CF, Chen S. Baseline hypertension: New insight into the potential predictors of survival in patients with hepatocellular carcinoma. International Journal of Cardiology 2013;168:2979-81. [DOI: 10.1016/j.ijcard.2013.04.106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
437 Chan A, Sertic M, Sammon J, Kim TK, Jang HJ, Guimaraes L, O'Malley M, Khalili K. Diagnostic imaging of hepatocellular carcinoma at community hospitals and their tertiary referral center in the era of LI-RADS: a quality assessment study. Abdom Radiol (NY) 2019;44:4028-36. [PMID: 31555846 DOI: 10.1007/s00261-019-02237-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Park MS, Han K, Kim SU. Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. Expert Review of Gastroenterology & Hepatology 2014;8:501-11. [DOI: 10.1586/17474124.2014.898563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
439 Forner A, Bruix J. East meets the West--portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2009;6:14-15. [PMID: 18981995 DOI: 10.1038/ncpgasthep1300] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
440 Carr BI, Pancoska P, Branch RA. Low alpha-fetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1543-1549. [PMID: 20796153 DOI: 10.1111/j.1440-1746.2010.06303.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
441 Jiang K, Dong J, Zhang W, Liu Y, Su M, Zhao X, Wang J, Yao M, Huang Z. Effect of one-off complete tumor radiofrequency ablation on liver function and postoperative complication in small hepatocellular carcinoma. European Journal of Surgical Oncology 2014;40:576-83. [DOI: 10.1016/j.ejso.2013.12.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
442 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
443 Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009;50:604-620. [PMID: 19157625 DOI: 10.1016/j.jhep.2008.12.011] [Cited by in Crossref: 381] [Cited by in F6Publishing: 361] [Article Influence: 29.3] [Reference Citation Analysis]
444 Lee MW, Rhim H, Cha DI, Kim YJ, Choi D, Kim YS, Lim HK. Percutaneous radiofrequency ablation of hepatocellular carcinoma: fusion imaging guidance for management of lesions with poor conspicuity at conventional sonography. AJR Am J Roentgenol. 2012;198:1438-1444. [PMID: 22623560 DOI: 10.2214/ajr.11.7568] [Cited by in Crossref: 76] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
445 Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features. RadioGraphics 2008;28:747-69. [DOI: 10.1148/rg.283055108] [Cited by in Crossref: 130] [Cited by in F6Publishing: 93] [Article Influence: 10.0] [Reference Citation Analysis]
446 Lin MT, Chang KC, Yen YH, Tsai MC, Chen CH, Wang JH, Hsiao CC, Chiu YH, Hu TH. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. J Formos Med Assoc 2021;120:621-8. [PMID: 32718890 DOI: 10.1016/j.jfma.2020.07.019] [Reference Citation Analysis]
447 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-54. [PMID: 25153274 DOI: 10.1148/radiol.14132361] [Cited by in Crossref: 236] [Cited by in F6Publishing: 204] [Article Influence: 33.7] [Reference Citation Analysis]
448 Yang DW, Jia XB, Xiao YJ, Wang XP, Wang ZC, Yang ZH. Noninvasive Evaluation of the Pathologic Grade of Hepatocellular Carcinoma Using MCF-3DCNN: A Pilot Study.Biomed Res Int. 2019;2019:9783106. [PMID: 31183380 DOI: 10.1155/2019/9783106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
449 杨薇. 影像引导射频消融治疗较大肝癌的现状及前景. 世界华人消化杂志 2015; 23(30): 4771-4777 [DOI: 10.11569/wcjd.v23.i30.4771] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
450 Sun P, Yang X, He RQ, Hu QG, Song ZF, Xiong J, Zheng QC. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials. Hepatol Res. 2014;44:259-269. [PMID: 23607290 DOI: 10.1111/hepr.12115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
451 Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology. 2012;55:141-152. [PMID: 21898502 DOI: 10.1002/hep.24652] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
452 Borzio M, Colloredo G, Pioltelli P, Quagliuolo M. Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis. 2007;39:1011-1017. [PMID: 17936698 DOI: 10.1016/j.dld.2007.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
453 Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268-1289. [PMID: 24681130 DOI: 10.1016/j.jhep.2014.01.021] [Cited by in Crossref: 618] [Cited by in F6Publishing: 642] [Article Influence: 88.3] [Reference Citation Analysis]
454 Yeo M, Na YM, Kim DK, Kim YB, Wang HJ, Lee JA, Cheong JY, Lee KJ, Paik YK, Cho SW. The loss of phenol sulfotransferase 1 in hepatocellular carcinogenesis. Proteomics 2010;10:266-76. [PMID: 19904771 DOI: 10.1002/pmic.200900721] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
455 Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver 2012;6:139-48. [PMID: 22570744 DOI: 10.5009/gnl.2012.6.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
456 Wang Y, Shang W, Zhong H, Luo T, Niu M, Xu K, Tian J. Tumor Vessel Targeted Self-Assemble Nanoparticles for Amplification and Prediction of the Embolization Effect in Hepatocellular Carcinoma. ACS Nano 2020;14:14907-18. [PMID: 33111520 DOI: 10.1021/acsnano.0c04341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
457 Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, Ewenstein B. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 2009;15:1197-209. [DOI: 10.1111/j.1365-2516.2009.02066.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
458 Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2019;25:52-64. [PMID: 30360031 DOI: 10.3350/cmh.2018.0040] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
459 Qi X, Zhang X, Li Z, Hui J, Xiang Y, Chen J, Zhao J, Li J, Qi FZ, Xu Y. HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma. Oncotarget 2016;7:62789-96. [PMID: 27566593 DOI: 10.18632/oncotarget.11558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
460 陈子瑶, 梁健, 邓鑫. 沙利度胺联合TACE治疗原发性肝癌疗效与安全性的系统评价. 世界华人消化杂志 2015; 23(2): 291-307 [DOI: 10.11569/wcjd.v23.i2.291] [Reference Citation Analysis]
461 Tsochatzis EA, Fatourou EM, Triantos CK, Burroughs AK. Transarterial Therapies for Hepatocellular Carcinoma. In: Vauthey J, Brouquet A, editors. Multidisciplinary Treatment of Hepatocellular Carcinoma. Berlin: Springer Berlin Heidelberg; 2013. pp. 195-206. [DOI: 10.1007/978-3-642-16037-0_13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
462 Le PH, Kuo CJ, Hsieh YC, Chen TH, Lin CL, Yeh CT, Liang KH. Ages of hepatocellular carcinoma occurrence and life expectancy are associated with a UGT2B28 genomic variation. BMC Cancer 2019;19:1190. [PMID: 31805979 DOI: 10.1186/s12885-019-6409-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
463 Zhu Q, Yuan B, Qiao G, Yan J, Li Y, Duan R, Yan Y. Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients. Clinics and Research in Hepatology and Gastroenterology 2016;40:418-27. [DOI: 10.1016/j.clinre.2015.12.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
464 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Reference Citation Analysis]
465 Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, Eng J, Bhagat N, Pawlik TM, Geschwind JF. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology. 2012;264:285-294. [PMID: 22627601 DOI: 10.1148/radiol.12112142] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
466 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
467 Ollivier I, Dauvois B, Guittet L, Boutreux S, Dupont B, Launoy G, Dao T. Survival improvement in Child–Pugh C cirrhotic patients with hepatocellular carcinoma diagnosed during 1990–2002. Gastroentérologie Clinique et Biologique 2010;34:288-96. [DOI: 10.1016/j.gcb.2010.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
468 Geier A, Schadde E, Müllhaupt B. [Current therapeutic strategies for hepatocellular carcinoma]. MMW Fortschr Med 2012;154:63-7; quiz 68-9. [PMID: 22957387 DOI: 10.1007/s15006-012-0931-4] [Reference Citation Analysis]
469 Pupulim LF, Hakimé A, Barrau V, Abdel-Rehim M, Zappa M, Vilgrain V. Fatty hepatocellular carcinoma: radiofrequency ablation--imaging findings. Radiology 2009;250:940-8. [PMID: 19164699 DOI: 10.1148/radiol.2502080858] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
470 de Baere T, Deschamps F. Arterial therapies of colorectal cancer metastases to the liver. Abdom Imaging 2011;36:661-70. [PMID: 21681492 DOI: 10.1007/s00261-011-9768-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
471 Kim BK, Ahn SH, Seong JS, Park JY, Kim do Y, Kim JK, Lee do Y, Lee KH, Han KH. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int. 2011;31:369-376. [PMID: 21083802 DOI: 10.1111/j.1478-3231.2010.02368.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
472 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 454] [Cited by in F6Publishing: 386] [Article Influence: 37.8] [Reference Citation Analysis]
473 Hasani FA, Knoepfli M, Gemperli A, Kollar A, Banz V, Kettenbach J, Jüni P, Dufour J. Factors affecting screening for hepatocellular carcinoma. Annals of Hepatology 2014;13:204-10. [DOI: 10.1016/s1665-2681(19)30883-x] [Cited by in Crossref: 12] [Article Influence: 1.7] [Reference Citation Analysis]
474 Song Q, Ren W, Fan L, Zhao M, Mao L, Jiang S, Zhao C, Cui Y. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection. Dig Dis Sci 2020;65:1266-75. [PMID: 31312995 DOI: 10.1007/s10620-019-05733-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
475 Goebel M, Singal AG, Nodora J, Castañeda SF, Martinez E, Doubeni C, Laiyemo A, Gupta S. How can we boost colorectal and hepatocellular cancer screening among underserved populations? Curr Gastroenterol Rep 2015;17:22. [PMID: 26031831 DOI: 10.1007/s11894-015-0445-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
476 Fassio E, Díaz S, Santa C, Elisa Reig M, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, Carlos de Souza F, Hernández N, Pinchuk L. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Annals of Hepatology 2010;9:63-9. [DOI: 10.1016/s1665-2681(19)31681-3] [Cited by in Crossref: 31] [Article Influence: 2.8] [Reference Citation Analysis]
477 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237-267. [PMID: 19501929 DOI: 10.1016/j.jhep.2009.04.009] [Cited by in Crossref: 1087] [Cited by in F6Publishing: 946] [Article Influence: 90.6] [Reference Citation Analysis]
478 Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, Iavarone M, Di Marco V, Farinati F, Del Poggio P, Borzio F. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Liver Dis. 2011;43:875-880. [PMID: 21684821 DOI: 10.1016/j.dld.2011.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
479 Marrero JA, Pelletier S. Hepatocellular Carcinoma. Clinics in Liver Disease 2006;10:339-51. [DOI: 10.1016/j.cld.2006.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
480 Lu X, Nie H, Li Y, Zhan C, Liu X, Shi X, Shi M, Zhang Y, Li Y. Comprehensive characterization and evaluation of hepatocellular carcinoma by LC–MS based serum metabolomics. Metabolomics 2015;11:1381-93. [DOI: 10.1007/s11306-015-0797-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
481 Minocha J, Lewandowski RJ. Assessing Imaging Response to Therapy. Radiologic Clinics of North America 2015;53:1077-88. [DOI: 10.1016/j.rcl.2015.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
482 Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8:192-199. [PMID: 19879972 DOI: 10.1016/j.cgh.2009.10.026] [Cited by in Crossref: 147] [Cited by in F6Publishing: 140] [Article Influence: 12.3] [Reference Citation Analysis]
483 Zhang L, Wang N, Shen Q, Cheng W, Qian GJ. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS One. 2013;8:e76119. [PMID: 24146824 DOI: 10.1371/journal.pone.0076119] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
484 Gabr A, Polineni P, Mouli SK, Riaz A, Lewandowski RJ, Salem R. Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma. Semin Nucl Med 2019;49:197-203. [PMID: 30954185 DOI: 10.1053/j.semnuclmed.2019.01.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
485 Makoyeva A, Kim TK, Jang HJ, Medellin A, Wilson SR. Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study. Radiol Imaging Cancer 2020;2:e190014. [PMID: 33778701 DOI: 10.1148/rycan.2020190014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
486 Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, Vogt A, Yildiz Y, Sievers E, Schmidt-Wolf IG, Caselmann WH. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology. 2008;48:157-168. [PMID: 18537185 DOI: 10.1002/hep.22296] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
487 Thapa RK, Choi JY, Poudel BK, Choi HG, Yong CS, Kim JO. Receptor-targeted, drug-loaded, functionalized graphene oxides for chemotherapy and photothermal therapy. Int J Nanomedicine 2016;11:2799-813. [PMID: 27358565 DOI: 10.2147/IJN.S105401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
488 Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Methodological assessment of HCC literature. Ann Oncol 2013;24 Suppl 2:ii6-14. [PMID: 23715943 DOI: 10.1093/annonc/mdt052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
489 Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, Zhou JX, Hu RM, Tan QY. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28:456-463. [PMID: 23216261 DOI: 10.1111/jgh.12088] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
490 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
491 Real M, Bianchi L, Vilana R, Burrel M, Rimola J. Tratamiento percutáneo e intraarterial del carcinoma hepatocelular. Radiología 2010;52:399-413. [DOI: 10.1016/j.rx.2010.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
492 Hessheimer AJ, Forner A, Varela M, Bruix J. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22:1239-1244. [PMID: 20505515 DOI: 10.1097/meg.0b013e32833aa19b] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
493 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-1327. [PMID: 18821591 DOI: 10.1002/hep.22506] [Cited by in Crossref: 747] [Cited by in F6Publishing: 711] [Article Influence: 57.5] [Reference Citation Analysis]
494 Numata K, Isozaki T, Morimoto M, Sugimori K, Kunisaki R, Morizane T, Tanaka K. Prospective study of differential diagnosis of hepatic tumors by pattern-based classification of contrast-enhanced sonography. World J Gastroenterol 2006; 12(39): 6290-6298 [PMID: 17072951 DOI: 10.3748/wjg.v12.i39.6290] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
495 Lin M, Liang S, Wang X, Liang Y, Zhang M, Chen J, Niu L, Xu K. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. Oncotarget. 2017;8:81967-81977. [PMID: 29137237 DOI: 10.18632/oncotarget.17804] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
496 Boal Carvalho P, Pereira E. Imagiological Diagnosis of Gastrointestinal Diseases - Diagnostic Criteria of Hepatocellular Carcinoma. GE Port J Gastroenterol 2015;22:153-60. [PMID: 28868398 DOI: 10.1016/j.jpge.2015.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
497 Song KD, Lim HK, Rhim H, Lee MW, Kim YS, Lee WJ, Paik YH, Gwak GY, Kim JM, Kwon CH. Repeated Hepatic Resection versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Hepatic Resection: A Propensity Score Matching Study. Radiology. 2015;275:599-608. [PMID: 25559235 DOI: 10.1148/radiol.14141568] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 7.5] [Reference Citation Analysis]
498 Wong YH, Tan HY, Kasbollah A, Abdullah BJJ, Yeong CH. Preparation and In Vitro Evaluation of Neutron-Activated, Theranostic Samarium-153-Labeled Microspheres for Transarterial Radioembolization of Hepatocellular Carcinoma and Liver Metastasis. Pharmaceutics 2019;11:E596. [PMID: 31718079 DOI: 10.3390/pharmaceutics11110596] [Reference Citation Analysis]
499 Ruan Y, Sun L, Hao Y, Wang L, Xu J, Zhang W, Xie J, Guo L, Zhou L, Yun X, Zhu H, Shen A, Gu J. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest 2012;122:2554-66. [PMID: 22653060 DOI: 10.1172/JCI58488] [Cited by in Crossref: 83] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
500 Ma GL, Bai RJ, Jiang HJ, Hao XJ, Dong XP, Li DQ, Liu XD, Wei L. Early changes of hepatic hemodynamics measured by functional CT perfusion in a rabbit model of liver tumor. Hepatobiliary Pancreat Dis Int. 2012;11:407-411. [PMID: 22893468 DOI: 10.1016/S1499-3872(12)60199-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
501 Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010;31:1409-20. [PMID: 20953207 DOI: 10.1038/aps.2010.142] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 9.4] [Reference Citation Analysis]
502 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73. [DOI: 10.1002/hep.23725] [Cited by in Crossref: 323] [Cited by in F6Publishing: 322] [Article Influence: 29.4] [Reference Citation Analysis]
503 Noh SJ, Lee HK, Yu HC, Moon WS. Exophytic combined hepatocellular carcinoma and cholangiocarcinoma. Clin Mol Hepatol 2012;18:416-9. [PMID: 23323259 DOI: 10.3350/cmh.2012.18.4.416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
504 Nojiri S, Fujiwara K, Shinkai N, Endo M, Joh T. Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI. World J Hepatol 2014; 6(12): 930-938 [PMID: 25544880 DOI: 10.4254/wjh.v6.i12.930] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
505 Oxentenko AS, Litin SC. Clinical Pearls in Gastroenterology. Mayo Clinic Proceedings 2009;84:906-11. [DOI: 10.4065/84.10.906] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
506 Khan A, Al Balwi MA, Tanaka Y, Hajeer A, Sanai FM, Al Abdulkarim I, Al Ayyar L, Badri M, Saudi D, Tamimi W, Mizokami M, Al Knawy B. Novel point mutations and mutational complexes in the enhancer II, core promoter and precore regions of hepatitis B virus genotype D1 associated with hepatocellular carcinoma in Saudi Arabia: HBV/D1 genomic variations and hepatocellular carcinoma. Int J Cancer 2013. [DOI: 10.1002/ijc.28307] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
507 Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg 2012;397:681-95. [DOI: 10.1007/s00423-012-0911-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
508 Ibrahim GH, Mahmoud MA, Aly NM. Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients. Mol Biol Rep. 2013;40:7069-7075. [PMID: 24186850 DOI: 10.1007/s11033-013-2829-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
509 Zhu K, Huang J, Lai L, Huang W, Cai M, Zhou J, Guo Y, Chen J. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology. 2018;288:300-307. [PMID: 29688153 DOI: 10.1148/radiol.2018172028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
510 Seror O. Percutaneous hepatic ablation: What needs to be known in 2014. Diagnostic and Interventional Imaging 2014;95:665-75. [DOI: 10.1016/j.diii.2014.04.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
511 Borzio M, Dionigi E, Rossini A, Marignani M, Sacco R, De Sio I, Bertolini E, Francica G, Giacomin A, Parisi G, Vicari S, Toldi A, Salmi A, Boccia S, Mitra M, Fornari F. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. Hepatology. 2018;67:2215-2225. [PMID: 29165831 DOI: 10.1002/hep.29662] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
512 Shen S, Peng H, Wang Y, Xu M, Lin M, Xie X, Peng B, Kuang M. Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis. BMC Cancer 2018;18:117. [PMID: 29386009 DOI: 10.1186/s12885-018-4011-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
513 Corma-gómez A, Morano L, Téllez F, Rivero-juárez A, Real LM, Alados JC, Ríos-villegas MJ, Vera-méndez FJ, Muñoz RP, Geijo P, Macías J, Pineda JA. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS 2019;33:1167-74. [DOI: 10.1097/qad.0000000000002186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
514 Liu YI, Kamaya A, Jeffrey RB, Shin LK. Multidetector Computed Tomography Triphasic Evaluation of the Liver Before Transplantation: Importance of Equilibrium Phase Washout and Morphology for Characterizing Hypervascular Lesions. Journal of Computer Assisted Tomography 2012;36:213-9. [DOI: 10.1097/rct.0b013e318247c8f0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
515 Sewell JL, Stick KM, Monto A. Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy. Eur J Gastroenterol Hepatol 2009;21:225-9. [PMID: 19212213 DOI: 10.1097/MEG.0b013e32831101b7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
516 Baleato-gonzález S, García-figueiras R. Criterios específicos de respuesta tumoral. Radiología 2018;60:64-81. [DOI: 10.1016/j.rx.2018.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
517 Liu Y, Ren Y, Ge S, Xiong B, Zhou G, Feng G, Song S, Zheng C. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome and Risk Signature Analysis. Front Oncol 2021;11:662408. [PMID: 34155478 DOI: 10.3389/fonc.2021.662408] [Reference Citation Analysis]
518 Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2174-2181. [PMID: 28474143 DOI: 10.1007/s10620-017-4595-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
519 Lee MW, Kim YJ, Park HS, Yu NC, Jung SI, Ko SY, Jeon HJ. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR Am J Roentgenol. 2010;194:W396-W400. [PMID: 20410384 DOI: 10.2214/ajr.09.3171] [Cited by in Crossref: 66] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
520 Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P, Gaeta GB, Leonardi C, Levrero M, Mazzotta F, Morrone A, Nosotti L, Prati D, Rapicetta M, Sagnelli E, Scotto G, Starnini G. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Digestive and Liver Disease 2011;43:589-95. [DOI: 10.1016/j.dld.2010.12.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
521 Alabraba E, Joshi H, Bird N, Griffin R, Sturgess R, Stern N, Sieberhagen C, Cross T, Camenzuli A, Davis R, Evans J, O'grady E, Palmer D, Diaz-nieto R, Fenwick S, Poston G, Malik H. Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. European Journal of Surgical Oncology 2019;45:1660-7. [DOI: 10.1016/j.ejso.2019.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
522 Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008;8:839-846. [PMID: 18318783 DOI: 10.1111/j.1600-6143.2007.02138.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 128] [Article Influence: 10.4] [Reference Citation Analysis]
523 Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. Journal of Hepatology 2015;62:363-70. [DOI: 10.1016/j.jhep.2014.08.045] [Cited by in Crossref: 107] [Cited by in F6Publishing: 106] [Article Influence: 17.8] [Reference Citation Analysis]
524 Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010;195:758-765. [PMID: 20729457 DOI: 10.2214/ajr.09.2954] [Cited by in Crossref: 166] [Cited by in F6Publishing: 76] [Article Influence: 15.1] [Reference Citation Analysis]
525 Sukato DC, Tohme S, Chalhoub D, Han K, Zajko A, Amesur N, Orons P, Marsh JW, Geller DA, Tsung A. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization. Journal of Vascular and Interventional Radiology 2015;26:816-824.e1. [DOI: 10.1016/j.jvir.2015.01.038] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
526 Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. Dig Liver Dis 2019;51:142-8. [PMID: 30076015 DOI: 10.1016/j.dld.2018.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
527 Chao Y, Wu CY, Kuo CY, Wang JP, Luo JC, Kao CH, Lee RC, Lee WP, Li CP. Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. Hepatol Int. 2013;7:883-892. [PMID: 26201926 DOI: 10.1007/s12072-012-9409-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
528 Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013; 19(24): 3872-3882 [PMID: 23840128 DOI: 10.3748/wjg.v19.i24.3872] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 85] [Article Influence: 11.5] [Reference Citation Analysis]
529 Wagner M, Doblas S, Daire J, Paradis V, Haddad N, Leitão H, Garteiser P, Vilgrain V, Sinkus R, Van Beers BE. Diffusion-weighted MR Imaging for the Regional Characterization of Liver Tumors. Radiology 2012;264:464-72. [DOI: 10.1148/radiol.12111530] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
530 Andreana L, Isgrò G, Pleguezuelo M, Germani G, Burroughs AK. Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol 2009; 1(1): 48-61 [PMID: 21160965 DOI: 10.4254/wjh.v1.i1.48] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
531 Trung TB, Hung VP, Hoang HT, Tung LM, Lee J. Detection of liver cancer cells by using ELISA and coupling of anti-glypican 3 antibody and magnetite nanoparticles. Geosystem Engineering 2015;18:219-25. [DOI: 10.1080/12269328.2015.1070698] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
532 Matsubara M, Shiraha H, Kataoka J, Iwamuro M, Horiguchi S, Nishina S, Takaoka N, Uemura M, Takaki A, Nakamura S. Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1602-1608. [PMID: 22554292 DOI: 10.1111/j.1440-1746.2012.07173.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
533 Silva M, Moya A, Berenguer M, Sanjuan F, López-Andujar R, Pareja E, Torres-Quevedo R, Aguilera V, Montalva E, De Juan M. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 2008;14:1449-1460. [PMID: 18825681 DOI: 10.1002/lt.21576] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 6.1] [Reference Citation Analysis]
534 Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol 2015; 7(2): 139-149 [PMID: 25729470 DOI: 10.4254/wjh.v7.i2.139] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 7.2] [Reference Citation Analysis]
535 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med 2019;8:3719-28. [PMID: 31127698 DOI: 10.1002/cam4.2241] [Cited by in Crossref: 39] [Cited by in F6Publishing: 52] [Article Influence: 19.5] [Reference Citation Analysis]
536 Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954-1961. [PMID: 19434742 DOI: 10.1002/hep.22870] [Cited by in Crossref: 262] [Cited by in F6Publishing: 246] [Article Influence: 21.8] [Reference Citation Analysis]
537 Su CW, Chan CC, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Tsay SH, Lee PC, Lee SD. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol. 2009;43:876-883. [PMID: 19247208 DOI: 10.1097/mcg.0b013e31818980ac] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
538 Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA. AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology 2013;58:2142-52. [PMID: 23775835 DOI: 10.1002/hep.26578] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
539 Song Y, Kim S, Lee H, No JH, Ryu HC, Kim J, Lim JW, Kim M, Choi I, Seo HR. Chromenopyrimidinone Controls Stemness and Malignancy by suppressing CD133 Expression in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1193. [PMID: 32397206 DOI: 10.3390/cancers12051193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
540 Tan CH, Low SC, Thng CH. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol. 2011;2011:519783. [PMID: 22007313 DOI: 10.4061/2011/519783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
541 Wang H, Yang J, Zhang K, Liu J, Li Y, Su W, Song N. Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets. Front Pharmacol 2021;12:650388. [PMID: 33935756 DOI: 10.3389/fphar.2021.650388] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
542 Zheng YS, Zhang JY, Zhang DH. Fatsioside A‑induced apoptotic death of HepG2 cells requires activation of AMP‑activated protein kinase. Mol Med Rep 2015;12:5679-84. [PMID: 26252753 DOI: 10.3892/mmr.2015.4194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
543 Chen YC, Jeng WJ, Chien RN, Chu CM, Liaw YF. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection. Aliment Pharmacol Ther 2016;43:1311-8. [PMID: 27072504 DOI: 10.1111/apt.13630] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
544 Lui HF. Screening for hepatocellular carcinoma. Int J Hepatol 2011;2011:363151. [PMID: 22028976 DOI: 10.4061/2011/363151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
545 Wang ZX, Li L, Tao FY. Health education helps to relieve postembolization pain during hepatic arterial chemoembolization therapy. J Pain Res 2018;11:2115-21. [PMID: 30319286 DOI: 10.2147/JPR.S166333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
546 Azer SA, Azer S. Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open 2016;6:e009889. [PMID: 26857105 DOI: 10.1136/bmjopen-2015-009889] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
547 Jiang K, Zhang W, Su M, Liu Y, Zhao X, Wang J, Yao M, Ogbonna J, Dong J, Huang Z. Laparoscopic radiofrequency ablation of solitary small hepatocellular carcinoma in the caudate lobe. European Journal of Surgical Oncology (EJSO) 2013;39:1236-42. [DOI: 10.1016/j.ejso.2013.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
548 Jeong S, Tong Y, Sha M, Gu J, Xia Q. Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget 2017;8:17292-300. [PMID: 28030846 DOI: 10.18632/oncotarget.14079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
549 Hyder O, Dodson RM, Weiss M, Cosgrove DP, Herman JM, Geschwind JH, Kamel IR, Pawlik TM. Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma. J Gastrointest Surg. 2013;17:1774-1783. [PMID: 23943387 DOI: 10.1007/s11605-013-2302-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
550 Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer 2017;123:751-8. [PMID: 27911488 DOI: 10.1002/cncr.30462] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
551 Dong J, Xu X, Ke M, Xiang J, Liu W, Liu X, Wang B, Zhang X, Lv Y. The FIB-4 score predicts postoperative short-term outcomes of hepatocellular carcinoma fulfilling the milan criteria. European Journal of Surgical Oncology (EJSO) 2016;42:722-7. [DOI: 10.1016/j.ejso.2016.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
552 Zhang L, Jiang G, Yao F, He Y, Liang G, Zhang Y, Hu B, Wu Y, Li Y, Liu H. Growth inhibition and apoptosis induced by osthole, a natural coumarin, in hepatocellular carcinoma. PLoS One 2012;7:e37865. [PMID: 22662241 DOI: 10.1371/journal.pone.0037865] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 8.1] [Reference Citation Analysis]
553 Lysy PA, Smets F, Sibille C, Najimi M, Sokal EM. Human skin fibroblasts: From mesodermal to hepatocyte-like differentiation. Hepatology. 2007;46:1574-1585. [PMID: 17969047 DOI: 10.1002/hep.28139] [Cited by in Crossref: 82] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
554 Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. Eur J Gastroenterol Hepatol 2017;29:706-15. [PMID: 28195873 DOI: 10.1097/MEG.0000000000000852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
555 Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29:3960-7. [PMID: 21911714 DOI: 10.1200/JCO.2011.37.1021] [Cited by in Crossref: 196] [Cited by in F6Publishing: 125] [Article Influence: 19.6] [Reference Citation Analysis]
556 Tian X, Dai Y, Wang DQ, Zhang L, Sui CG, Meng FD, Jiang SY, Liu YP, Jiang YH. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. Drug Des Devel Ther 2015;9:4431-40. [PMID: 26309396 DOI: 10.2147/DDDT.S86629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
557 Cruite I, Tang A, Sirlin CB. Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol. 2013;201:41-55. [PMID: 23789657 DOI: 10.2214/ajr.13.10570] [Cited by in Crossref: 52] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
558 Xu R, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey B, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu J, Hao X, Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nature Mater 2017;16:1155-61. [DOI: 10.1038/nmat4997] [Cited by in Crossref: 282] [Cited by in F6Publishing: 283] [Article Influence: 70.5] [Reference Citation Analysis]
559 Zhang YF, Zhou J, Wei W, Zou RH, Chen MS, Lau WY, Shi M, Guo RP. Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. Br J Cancer. 2016;115:1039-1047. [PMID: 27701389 DOI: 10.1038/bjc.2016.301] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
560 Eller A, Schmid A, Schmidt J, May M, Brand M, Saake M, Uder M, Lell M. Local control of perivascular malignant liver lesions using percutaneous irreversible electroporation: initial experiences. Cardiovasc Intervent Radiol. 2015;38:152-159. [PMID: 24798135 DOI: 10.1007/s00270-014-0898-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
561 van der Meer AJ, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Ieluzzi D. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut. 2015;64:322-331. [PMID: 24815676 DOI: 10.1136/gutjnl-2013-305357] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
562 Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:328-343. [PMID: 21452290 DOI: 10.1002/hep.24330] [Cited by in Crossref: 354] [Cited by in F6Publishing: 258] [Article Influence: 35.4] [Reference Citation Analysis]
563 Zhou Q, Li Z, Zhou J, Joshi BP, Li G, Duan X, Kuick R, Owens SR, Wang TD. In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. Photoacoustics 2016;4:43-54. [PMID: 27766208 DOI: 10.1016/j.pacs.2016.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
564 Kim YK, Kim CS, Han YM, Park G. Detection of Small Hepatocellular Carcinoma: Can Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Replace Combining Gadopentetate Dimeglumine-Enhanced and Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging? Investigative Radiology 2010;45:740-6. [DOI: 10.1097/rli.0b013e3181e943a7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
565 Mikami S, Tateishi R, Akahane M, Asaoka Y, Kondo Y, Goto T, Shiina S, Yoshida H, Koike K. Computed tomography follow-up for the detection of hepatocellular carcinoma recurrence after initial radiofrequency ablation: a single-center experience. J Vasc Interv Radiol. 2012;23:1269-1275. [PMID: 22999746 DOI: 10.1016/j.jvir.2012.06.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
566 Aarås AM, Reitan-Gjersøe TA, Waage A, Mala T, Edwin B, Løberg EM, Abildgaard A, Røsok BI. Laparoscopic resection of recurrent ectopic hepatocellular carcinoma: A case report with review of the literature and guidelines for follow-up. Int J Surg Case Rep 2015;17:92-5. [PMID: 26590353 DOI: 10.1016/j.ijscr.2015.10.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
567 Han C, Yu T, Qin W, Liao X, Huang J, Liu Z, Yu L, Liu X, Chen Z, Yang C, Wang X, Mo S, Zhu G, Su H, Li J, Qin X, Gui Y, Mo Z, Li L, Peng T. Genome-wide association study of the TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and infection with hepatitis B virus. J Gastrointest Oncol 2020;11:1333-49. [PMID: 33457005 DOI: 10.21037/jgo-20-510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
568 Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med. 2008;29:130-143. [PMID: 18061252 DOI: 10.1016/j.mam.2007.09.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
569 Gormez A, Eldem FG, Salanci BV, Bozkurt MF, Ugur O, Peynircioglu B. Utility of 'dual phase' cone beam computed tomography during radioembolisation in patients with hepatocellular carcinoma: what is really changing in flow dynamics before and after 90Y delivery? Pol J Radiol 2020;85:e21-8. [PMID: 32180850 DOI: 10.5114/pjr.2020.92915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
570 Trinchet J, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Goria O, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Blanc J, Abergel A, Serfaty L, Mallat A, Grangé J, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S; and the ANRS CO12 CirVir Group. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort): HEPATOLOGY, Vol. XX, No. X, 2015 TRINCHET ET AL. Hepatology 2015;62:737-50. [DOI: 10.1002/hep.27743] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 10.2] [Reference Citation Analysis]
571 Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma CY, Hua SC, Yang M, Yuan Q. microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Lett. 2011;585:1828-1834. [PMID: 21530512 DOI: 10.1016/j.febslet.2011.04.040] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
572 Sato M, Tateishi R, Yasunaga H, Matsui H, Fushimi K, Ikeda H, Yatomi Y, Koike K. In-hospital mortality associated with transcatheter arterial embolization for treatment of hepatocellular carcinoma in patients on hemodialysis for end stage renal disease: a matched-pair cohort study using a nationwide database. BJR Open. 2019;1:20190004. [PMID: 33178938 DOI: 10.1259/bjro.20190004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
573 Notarnicola M, Messa C, Refolo MG, Tutino V, Miccolis A, Caruso MG. Polyunsaturated fatty acids reduce fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene expression and promote apoptosis in HepG2 cell line. Lipids Health Dis 2011;10:10. [PMID: 21244676 DOI: 10.1186/1476-511X-10-10] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
574 Brunello F, Carucci P, Gaia S, Rolle E, Brunocilla PR, Castiglione A, Ciccone G, Rizzetto M. Local Tumor Progression of Hepatocellular Carcinoma After Microwave Percutaneous Ablation: A Preliminary Report. Gastroenterology Res 2012;5:28-32. [PMID: 27785175 DOI: 10.4021/gr401w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
575 Xiong W, Cheeney G, Kim S, Kolesnikova V, Henninger B, Alexander J, Swanson PE, Upton MP, Truong CD, Yeh MM. Radiologically Undetected Hepatocellular Carcinoma in Patients Undergoing Liver Transplantation: An Immunohistochemical Correlation With LI-RADS Score. Am J Surg Pathol 2017;41:1466-72. [PMID: 28914714 DOI: 10.1097/PAS.0000000000000955] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
576 Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget 2015;6:21193-207. [PMID: 26098859 DOI: 10.18632/oncotarget.4176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
577 Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Yoshida H, Aoki T, Hasegawa K, Akahane M, Ohtomo K, Fukayama M, Koike K, Kokudo N. Diagnostic accuracy of α-fetoprotein and des-γ-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates: AFP and DCP in transplant candidates. Hepatology Research 2011;41:1199-207. [DOI: 10.1111/j.1872-034x.2011.00871.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
578 Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T, Takawa M, Nagamatsu H, Imai Y. Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Can J Gastroenterol Hepatol 2018;2018:4756147. [PMID: 29974040 DOI: 10.1155/2018/4756147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
579 Abrishami A, Nasseri-moghaddam S, Eghtesad B, Sherman M, Abrishami A. Surgical resection for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd006935] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
580 Yamamoto N, Okano K, Kushida Y, Deguchi A, Yachida S, Suzuki Y. Clinicopathology of recurrent hepatocellular carcinomas after radiofrequency ablation treated with salvage surgery. Hepatol Res. 2014;44:1062-1071. [PMID: 23957810 DOI: 10.1111/hepr.12223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
581 Vilgrain V. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: hepatocellular carcinoma: imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci. 2010;17:374-379. [PMID: 19924373 DOI: 10.1007/s00534-009-0230-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
582 Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106:1439-1445. [PMID: 22433965 DOI: 10.1038/bjc.2012.92] [Cited by in Crossref: 209] [Cited by in F6Publishing: 216] [Article Influence: 23.2] [Reference Citation Analysis]
583 Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol. 2013;25:180-186. [PMID: 23044808 DOI: 10.1097/meg.0b013e328359e550] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
584 Zhou RU, Cai Y, Yang YI, Xiang J, Chen Z. Hepatoid adenocarcinoma of the stomach: A case report and review of the literature. Oncol Lett. 2015;9:2126-2128. [PMID: 26137025 DOI: 10.3892/ol.2015.2979] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
585 Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl. 2006;12:1028-1036. [PMID: 16799950 DOI: 10.1002/lt.20833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
586 Eltawil KM, Berry R, Abdolell M, Molinari M. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. HPB (Oxford) 2012;14:162-70. [PMID: 22321034 DOI: 10.1111/j.1477-2574.2011.00420.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
587 Woeste MR, Geller AE, Martin RCG 2nd, Polk HC Jr. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Ann Surg Oncol 2021;28:1499-510. [PMID: 33393028 DOI: 10.1245/s10434-020-09414-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
588 Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:23-33. [PMID: 21115578 DOI: 10.1634/theoncologist.2010-s4-23] [Cited by in Crossref: 79] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
589 Madhoun MF, Fazili J, Bright BC, Bader T, Roberts DN, Bronze MS. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci. 2010;339:169-173. [PMID: 20087166 DOI: 10.1097/maj.0b013e3181c4af27] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
590 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 154] [Article Influence: 21.9] [Reference Citation Analysis]
591 Zhao Z, Zhen M, Zhou C, Li L, Jia W, Liu S, Li X, Liao X, Wang C. A gadofullerene based liver-specific MRI contrast agent for an early diagnosis of orthotopic hepatocellular carcinoma. J Mater Chem B 2021;9:5722-8. [PMID: 34231648 DOI: 10.1039/d1tb00931a] [Reference Citation Analysis]
592 Piscaglia F, Leoni S, Cabibbo G, Borghi A, Imbriaco G, Golfieri R, Bolondi L. Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. Digestive and Liver Disease 2010;42:729-34. [DOI: 10.1016/j.dld.2010.03.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
593 Forner A, Raoul J. Non-invasive diagnostic criteria for hepatocellular carcinoma: The value of contrast washout at imaging and the death of alpha-fetoprotein. Liver International 2011;31:1419-21. [DOI: 10.1111/j.1478-3231.2011.02605.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
594 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int 2016;36:817-26. [DOI: 10.1111/liv.13071] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
595 Li X, Guo W, Guo L, Lau WY, Ge N, Wang K, Cheng S. Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study. Oncotarget 2018;9:24537-47. [PMID: 29849959 DOI: 10.18632/oncotarget.25224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
596 Zhang Y, Liang H, Chen M, Guo R, Li J, Zheng Y, Zhang Y, Lau WY. Hepatocellular Carcinoma Treated with Radiofrequency Ablation with or without Ethanol Injection: A Prospective Randomized Trial. Radiology 2007;244:599-607. [DOI: 10.1148/radiol.2442060826] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 7.4] [Reference Citation Analysis]
597 Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D. Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 2007;17:2519-30. [DOI: 10.1007/s00330-007-0602-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
598 Hwang J, Kim SH, Lee MW, Lee JY. Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol 2012;85:e314-22. [PMID: 22167508 DOI: 10.1259/bjr/27727228] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
599 Haruki K, Shiba H, Saito N, Horiuchi T, Shirai Y, Fujiwara Y, Furukawa K, Sakamoto T, Yanaga K. Risk stratification using a novel liver functional reserve score of combination prothrombin time-international normalized ratio to albumin ratio and albumin in patients with hepatocellular carcinoma. Surgery 2018;164:404-10. [PMID: 29754978 DOI: 10.1016/j.surg.2018.02.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
600 Kakita N, Kanto T, Itose I, Kuroda S, Inoue M, Matsubara T, Higashitani K, Miyazaki M, Sakakibara M, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells. Int J Cancer 2012;131:2573-83. [PMID: 22419479 DOI: 10.1002/ijc.27535] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
601 Ruff SM, Khader A, Conte C, Kadison A, Sullivan J, Wang J, Zaidi R, Deutsch GB. Improved outcomes with surgery compared to radiofrequency ablation in the treatment of resectable hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2019;31:1397-402. [PMID: 30985455 DOI: 10.1097/MEG.0000000000001416] [Reference Citation Analysis]
602 Akamatsu N, Kokudo N. Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor. Hepatobiliary Surg Nutr 2016;5:422-8. [PMID: 27826557 DOI: 10.21037/hbsn.2016.08.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
603 Li J, Huang S, Zhou Z, Lin W, Chen S, Chen M, Ye Y. Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma. Cancer Manag Res 2018;10:4945-57. [PMID: 30464595 DOI: 10.2147/CMAR.S178326] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
604 Pang G, Shao C, Lv Y, Zhao F. Tumor attenuation and quantitative analysis of perfusion parameters derived from tri-phasic CT scans in hepatocellular carcinoma: Relationship with histological grade. Medicine (Baltimore) 2021;100:e25627. [PMID: 33879737 DOI: 10.1097/MD.0000000000025627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
605 Lo CH, Huang WY, Lee MS, Lin KT, Lin TP, Chang PY, Fan CY, Jen YM. Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization. Eur J Gastroenterol Hepatol. 2014;26:345-352. [PMID: 24384685 DOI: 10.1097/meg.0000000000000032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
606 Ying ZL, Li XJ, Dang H, Wang F, Xu XY. Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells. Exp Ther Med. 2014;7:1354-1358. [PMID: 24940438 DOI: 10.3892/etm] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
607 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2014;44:608-620. [PMID: 23701455 DOI: 10.1111/hepr.12169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
608 Quaia E, De Paoli L, Pizzolato R, Angileri R, Pantano E, Degrassi F, Ukmar M, Cova MA. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase. AJR Am J Roentgenol. 2013;200:553-562. [PMID: 23436844 DOI: 10.2214/ajr.12.8818] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
609 Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep. 2008;10:60-66. [PMID: 18417044 DOI: 10.1007/s11894-008-0010-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
610 Byrnes V, Shi H, Kiryu S, Rofsky NM, Afdhal NH. The Clinical Outcome of Small (<20 mm) Arterially Enhancing Nodules on MRI in the Cirrhotic Liver. Am J Gastroenterology 2007;102:1654-9. [DOI: 10.1111/j.1572-0241.2007.01338.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
611 Whang-peng J, Cheng A, Hsu C, Chen C. Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental & Clinical Medicine 2010;2:93-103. [DOI: 10.1016/s1878-3317(10)60016-2] [Cited by in Crossref: 18] [Article Influence: 1.6] [Reference Citation Analysis]
612 Song J, Lee YN, Kim YS, Kim SG, Jin SJ, Park JM, Choi GS, Chung JC, Lee MH, Cho YH, Choi MH, Kim DC, Choi HJ, Moon JH, Lee SH, Jeong SW, Jang JY, Kim HS, Kim BS. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors. Nuclear Medicine Communications 2015;36:319-27. [DOI: 10.1097/mnm.0000000000000254] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
613 Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Furuta M, Tsunoda T, Miyano S, Kubo M, Aikata H, Ochi H, Kawakami YI, Arihiro K, Ohdan H, Nakagawa H, Chayama K. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cell Mol Gastroenterol Hepatol. 2015;1:516-534. [PMID: 28210698 DOI: 10.1016/j.jcmgh.2015.06.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
614 Maiwald B, Lobsien D, Kahn T, Stumpp P. Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma? PLoS One. 2014;9:e111935. [PMID: 25375778 DOI: 10.1371/journal.pone.0111935] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
615 Liu W, Qin J, Guo R, Xie S, Jiang H, Wang X, Kang Z, Wang J, Shan H. Accuracy of the diagnostic evaluation of hepatocellular carcinoma with LI-RADS. Acta Radiol. 2018;59:140-146. [PMID: 28648125 DOI: 10.1177/0284185117716700] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
616 Watanabe A, Ramalho M, AlObaidy M, Kim HJ, Velloni FG, Semelka RC. Magnetic resonance imaging of the cirrhotic liver: An update. World J Hepatol 2015; 7(3): 468-487 [PMID: 25848471 DOI: 10.4254/wjh.v7.i3.468] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
617 Hatanaka T, Arai H, Shibasaki M, Tojima H, Takizawa D, Toyoda M, Takayama H, Abe T, Sato K, Kakizaki S. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: A retrospective cohort study. Hepatol Res. 2018;48:165-175. [PMID: 28500686 DOI: 10.1111/hepr.12912] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
618 Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer. 2017;6:204-215. [PMID: 28626732 DOI: 10.1159/000452846] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 15.5] [Reference Citation Analysis]
619 Blaschke EM, Rao VL, Xiong L, Te HS, Hart J, Reddy KG, Oto A. Multiphase Multi–Detector Row Computed Tomography Imaging Characteristics of Large (>5 cm) Focal Hepatocellular Carcinoma: . Journal of Computer Assisted Tomography 2016;40:493-7. [DOI: 10.1097/rct.0000000000000379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
620 Aranda-Michel J, Dickson RC, Bonatti H, Crossfield JR, Keaveny AP, Vasquez AR. Patient selection for liver transplant: 1-year experience with 555 patients at a single center. Mayo Clin Proc 2008;83:165-8. [PMID: 18241626 DOI: 10.4065/83.2.165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
621 Martin AN, Wilkins LR, Das D, Johnston LE, Bauer TW, Adams RB, Zaydfudim VM. Efficacy of Radiofrequency Ablation versus Transarterial Chemoembolization for Patients with Solitary Hepatocellular Carcinoma ≤3 cm. The American Surgeon 2019;85:150-5. [DOI: 10.1177/000313481908500220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
622 Tsan Y, Lee C, Wang J, Chen P. Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection. JCO 2012;30:623-30. [DOI: 10.1200/jco.2011.36.0917] [Cited by in Crossref: 184] [Cited by in F6Publishing: 98] [Article Influence: 20.4] [Reference Citation Analysis]
623 Hiraoka A, Michitaka K, Horiike N, Hidaka S, Uehara T, Ichikawa S, Hasebe A, Miyamoto Y, Ninomiya T, Sogabe I, Ishimaru Y, Kawasaki H, Koizumi Y, Hirooka M, Yamashita Y, Abe M, Hiasa Y, Matsuura B, Onji M. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol. 2010;25:403-407. [PMID: 19929922 DOI: 10.1111/j.1440-1746.2009.06037.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
624 Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, Yang J, He J. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2012;138:455-62. [DOI: 10.1007/s00432-011-1117-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
625 Tang S, Liu Z, Zhang Y, He Y, Pan D, Liu Y, Liu Q, Zhang Z, Yuan Y. Rather than Rs1800796 polymorphism, expression of interleukin-6 is associated with disease progression of chronic HBV infection in a Chinese Han population. Dis Markers 2013;35:799-805. [PMID: 24371367 DOI: 10.1155/2013/508023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
626 Zhao WC, Yang N, Zhu N, Zhang HB, Fu Y, Zhou HB, Cai WK, Chen BD, Yang GS. Patients with multiple hepatocellular carcinomas within the UCSF criteria have outcomes after curative resection similar to patients within the BCLC early-stage criteria. World J Surg. 2012;36:1811-1823. [PMID: 22526045 DOI: 10.1007/s00268-012-1601-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
627 Lee J, Yoo SH, Sohn W, Kim HW, Choi YS, Won JH, Heo JY, Park SJ, Park YM. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B. Clin Mol Hepatol 2016;22:339-49. [PMID: 27729627 DOI: 10.3350/cmh.2016.0021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
628 Hiraoka A, Kumada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Yokohama K, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M. Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer 2020;9:73-83. [PMID: 32071911 DOI: 10.1159/000503031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
629 Fransen van de Putte DE, Makris M, Fischer K, Yee TT, Kirk L, van Erpecum KJ, Patch D, Posthouwer D, Mauser-bunschoten EP. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. Journal of Hepatology 2014;60:39-45. [DOI: 10.1016/j.jhep.2013.08.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
630 Chelis L, Ntinos N, Souftas V, Deftereos S, Xenidis N, Chamalidou E, Maltezos E, Kakolyris S. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report. Med Oncol. 2011;28 Suppl 1:S165-S168. [PMID: 20809183 DOI: 10.1007/s12032-010-9669-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
631 Celli N, Gaiani S, Piscaglia F, Zironi G, Camaggi V, Leoni S, Righini R, Bolondi L. Characterization of liver lesions by real-time contrast-enhanced ultrasonography. Eur J Gastroenterol Hepatol. 2007;19:3-14. [PMID: 17206071 DOI: 10.1097/01.meg.0000250585.53608.3c] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
632 Lachenmayer A, Alsinet C, Chang CY, Llovet JM. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S264-S272. [PMID: 20547313 DOI: 10.1016/s1590-8658(10)60515-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
633 Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 2014;134:342-351. [PMID: 23825037 DOI: 10.1002/ijc.28372] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
634 Kim JH, Kim PN, Won HJ, Shin YM. Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of hepatocellular carcinoma. AJR Am J Roentgenol. 2012;198:471-476. [PMID: 22268196 DOI: 10.2214/ajr.11.6583] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
635 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol. 2017;32:687-694. [PMID: 27577675 DOI: 10.1111/jgh.13589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
636 Maida M, Macaluso FS, Galia M, Cabibbo G. Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. World J Hepatol 2013; 5(12): 696-700 [PMID: 24409337 DOI: 10.4254/wjh.v5.i12.696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
637 Wang C, Teng Z, Zhu Y, Zhao AZ, Sun C. Associations between pre-S deletion mutation of hepatitis B virus and risk of hepatocellular carcinoma in the Asian population: a meta-analysis. Med Sci Monit. 2015;21:1072-1077. [PMID: 25868851 DOI: 10.12659/msm.894058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
638 Chen L, Ni C, Chen S, Cao J, Zhu H, Guo J, Zhu G, Zhong B, Ding W, He S, Deng G, Teng G. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. Journal of Vascular and Interventional Radiology 2016;27:1288-97. [DOI: 10.1016/j.jvir.2015.12.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
639 Peng M, Xu S, Zhang Y, Zhang L, Huang B, Fu S, Xue Z, Da Y, Dai Y, Qiao L, Dong A, Zhang R, Meng W. Thermosensitive Injectable Hydrogel Enhances the Antitumor Effect of Embelin in Mouse Hepatocellular Carcinoma. Journal of Pharmaceutical Sciences 2014;103:965-73. [DOI: 10.1002/jps.23885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
640 Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Postoperative prognostic nutritional index change is an independent predictor of survival in patients with small hepatocellular carcinoma. Am J Surg 2016;212:122-7. [PMID: 26421412 DOI: 10.1016/j.amjsurg.2015.06.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
641 Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol. 2009;43:482-488. [PMID: 19197197 DOI: 10.1097/mcg.0b013e318182015a] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
642 Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tokita M. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010;76:460-466. [PMID: 19427743 DOI: 10.1016/j.ijrobp.2009.02.030] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 6.7] [Reference Citation Analysis]
643 Yoo D, Kim KM, Jin Y, Shim JH, Ko G, Yoon H, Sung K, Lee J, Kang Y, Lim Y, Lee HC, Chung Y, Lee YS, Suh DJ. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?: Efficacy of TACE in HCC with metastasis. Journal of Gastroenterology and Hepatology 2011;26:145-54. [DOI: 10.1111/j.1440-1746.2010.06341.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 6.6] [Reference Citation Analysis]
644 Xie F, Zhang X, Li H, Zheng T, Xu F, Shen R, Yan L, Yang J, He J. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One. 2012;7:e42879. [PMID: 22916174 DOI: 10.1371/journal.pone.0042879] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
645 Wachter DL, Kristiansen G, Soll C, Hellerbrand C, Breuhahn K, Fritzsche F, Agaimy A, Hartmann A, Riener MO. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology. 2012;60:278-286. [PMID: 22211286 DOI: 10.1111/j.1365-2559.2011.04091.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
646 Cabibbo G, Rolle E, De Giorgio M, Genco C, Pressiani T, Spada F, Sacco R. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev Anticancer Ther. 2011;11:1807-1816. [PMID: 22049974 DOI: 10.1586/era.11.139] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
647 Tsai MC, Chen KD, Wang CC, Huang KT, Wu CH, Kuo IY, Chen LY, Hu TH, Goto S, Nakano T, Dorling A, McVey JH, Chen CL, Lin CC. Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling. Cell Death Discov 2015;1:15051. [PMID: 27551480 DOI: 10.1038/cddiscovery.2015.51] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
648 Nakazawa T, Hidaka H, Shibuya A, Koizumi W. Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. Case Rep Oncol. 2010;3:298-303. [PMID: 21347197 DOI: 10.1159/000319831] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
649 Kim DY, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:56-60. [PMID: 22212937 DOI: 10.1159/000333261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
650 Shirata C, Kokudo T, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, Kokudo N, Hasegawa K. Albumin-Indocyanine Green Evaluation (ALICE) grade combined with portal hypertension to predict post-hepatectomy liver failure. Hepatol Res. 2019;49:942-949. [PMID: 30849786 DOI: 10.1111/hepr.13327] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
651 Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis. 2007;11:817-837, viii. [PMID: 17981230 DOI: 10.1016/j.cld.2007.08.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
652 Yang T, Lin C, Zhai J, Shi S, Zhu M, Zhu N, Lu JH, Yang GS, Wu MC. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. J Cancer Res Clin Oncol. 2012;138:1121-1129. [PMID: 22402598 DOI: 10.1007/s00432-012-1188-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
653 Song KD, Lee MW, Rhim H, Kim YS, Kang TW, Shin SW, Cho SK. Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma After Combined Transarterial Chemoembolization and Radiofrequency Ablation. AJR Am J Roentgenol. 2016;207:1122-1127. [PMID: 27575338 DOI: 10.2214/ajr.16.16080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
654 Yamamoto N, Yamasaki T, Takami T, Uchida K, Fujisawa K, Matsumoto T, Saeki I, Terai S, Sakaida I. Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib. J Clin Biochem Nutr. 2016;58:202-209. [PMID: 27257345 DOI: 10.3164/jcbn.15-127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
655 Xiao CL, Tao ZH, Guo L, Li WW, Wan JL, Sun HC, Wang L, Tang ZY, Fan J, Wu WZ. Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice. BMC Cancer 2011;11:150. [PMID: 21513518 DOI: 10.1186/1471-2407-11-150] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
656 Xia L, Mo P, Huang W, Zhang L, Wang Y, Zhu H, Tian D, Liu J, Chen Z, Zhang Y, Chen Z, Hu H, Fan D, Nie Y, Wu K. The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis 2012;33:2250-9. [PMID: 22831955 DOI: 10.1093/carcin/bgs249] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 7.7] [Reference Citation Analysis]
657 Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW, Lee HS. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol. 2015;30:696-705. [PMID: 25250761 DOI: 10.1111/jgh.12788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
658 Yang J, Yang J, Yan L, Wen T, Li B, Wang W. Hepatic resection vs. transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria with portal hypertension. Digestive and Liver Disease 2018;50:713-9. [DOI: 10.1016/j.dld.2018.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
659 Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int 2009;3:480-9. [PMID: 19669251 DOI: 10.1007/s12072-009-9132-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
660 Furlan A, Marin D, Cabassa P, Taibbi A, Brunelli E, Agnello F, Lagalla R, Brancatelli G. Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: Intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD) guidelines. European Journal of Radiology 2012;81:2099-105. [DOI: 10.1016/j.ejrad.2011.07.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
661 Zhang X, Jia J, Dong J, Yu F, Ma N, Li M, Liu X, Liu W, Li T, Liu D. HLA-DQ polymorphisms with HBV infection: different outcomes upon infection and prognosis to lamivudine therapy. J Viral Hepat. 2014;21:491-498. [PMID: 24750255 DOI: 10.1111/jvh.12159] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
662 Brown DB, Chapman WC, Cook RD, Kerr JR, Gould JE, Pilgram TK, Darcy MD. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol. 2008;190:608-615. [PMID: 18287429 DOI: 10.2214/ajr.07.2879] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [